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3 INTRODUCTION 
“Human cancers result from the accumulation of genetic alterations at specific 
chromosomal regions involving a multistep process” (2). For a long time mutations seemed 
to be the most important alterations in lung cancer cells. However, in recent years it has 
been shown that epigenetic changes, especially changes in DNA methylation patterns play 
an important role in the pathogenesis of malignant diseases. Both, hypomethylation of 
transcriptional inactive genomic regions and hypermethylation of cytosine- guanine (CpG) 
rich areas, called CpG islands, which are mostly located 5’ of the transcription start site of 
actively transcribed genes, are frequently occurring changes in lung cancer cells (3-6). 
Alterations of DNA methylation patterns appear to be of tremendous importance in all steps 
of lung cancer pathogenesis occurring already in pre-carcinogenous lesions. 
To analyze the alteration in DNA methylation patterns mainly primary NSCLC samples 
obtained from surgeries are used. However, DNA methylation cannot only be detected in 
primary NSCLC samples but also in blood, sputum, bronchial brushings, and 
bronchioloalveolar lavage (BAL) samples from NSCLC patients (7-14). 
Costello et al. (15) reported that on average 600 CpG islands are targets for methylation 
in tumor cells. So far only ~ 150 genes were identified to be tumor-specifically methylated in 
NSCLC. Thus, increasing interest in large-scale and genome-wide analyze methods arose in 
recent years. Genome-wide methylation assays were developed mostly based on two 
methods. On the one hand on pharmacological re-activation of epigenetically regulated 
genes combined with gene expression microarray analysis and on the other hand on 
microarray analyses of DNA fragments after immunoprecipitation of methylated DNA 
fragments.  
In this project two genome-wide methods are used to analyze DNA methylation in three 
adenocarcinoma cell lines (A549, NCI-H1993 and NCI-H2073). Results are verified with 
methylation specific PCR (MSP) to identify so far unknown targets for DNA methylation in 
NSCLC.  
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4  AIM OF STUDY 
Silencing of certain tumor suppressor genes mediated by DNA methylation is a critical 
event in the pathogenesis of NSCLC. To date about ~150 genes are known targets for 
methylation in NSCLC. However, it has been reported that on average 600 CpG islands are 
methylated in a tumor (15). So far, DNA methylation in lung cancer was mainly investigated 
by single-gene methylation analyses. To get further insight into the significance of DNA 
methylation mediated gene silencing in NSCLC, we propose the following hypotheses: 
 Hypothesis 1:  The overwhelming majority of methylated genes in NSCLC are still 
unknown. 
 Hypothesis 2:  Methylation of unknown target genes in NSCLC is tumor-specific. 
 Hypothesis 3:  Methylated genes are involved in certain molecular pathways whose 
depletion may lead to the development of a malignant phenotype. 
 
Ad hypothesis 1: Investigations of the methylation status of single genes revealed that 
DNA methylation plays an important role in the pathogenesis of NSCLC. Whole genome 
approaches allow the search for methylated genes in NSCLC on a large scale approach.  
Thus, we performed a high-throughput search for genes whose expression is up-
regulated by epigenetically active drugs in 3 NSCLC cell lines. This assay is based on the 
observation that epigenetic modifications are reversible. Therefore, we treated the NSCLC 
cell lines A549, NCI-H1993 and NCI-H2073 with the DNA methyltransferase inhibitor 5-aza-
2´-deoxycytidine (Aza-dC) and/or the histone deacetylase inhibitor trichostatin A (TSA). 
Subsequently, Affymetix microarray analyses were performed using Affymetrix U133 plus 2.0 
arrays.  
For the vast majority of up-regulated genes the finding that they are inactivated by 
methylation will be new suggesting that these results will enhance our understanding of the 
molecular pathogenesis of NSCLC.   
Ad hypothesis 2: We established an approach for whole genome analysis of DNA 
methylation: methylated DNA immunoprecipitation (MeDIP) combined with microarray 
analysis (MeDIP-chip). This approach is based on enrichment of methylated DNA fragments 
Aim of study   
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using an anti-5-methylcytosine antibody followed by hybridization to CpG island microarrays. 
Using this approach we analyze the methylation patterns of 3 NSCLC cell lines and normal 
human bronchial epithelial cells (NHBEC) and compare the results to identify tumor-
specifically methylated genes. Tumor-specific methylation of selected genes is confirmed by 
methylation-specific PCR in a set of primary tumor and corresponding non-malignant lung 
tissue samples of 10 NSCLC patients. 
Ad hypothesis 3: Additionally, we want to identify the function of genes silenced by DNA 
methylation and their relevance in cancer related pathways. For this purpose in silico 
analysis are performed for Gene Ontology (GO) term enrichment.  
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5 BACKGROUND 
5.1 Epigenetics: Histone protein modifications and DNA 
methylation  
Literally “epi- (Greek: επί- over, above) genetic” incorporates all mechanisms that 
regulate gene expression but do not alter the DNA sequence itself leading to inheritable 
changes in the phenotype (16). Apart from methylation of the DNA strand itself, histone 
proteins can be modified in several different ways including methylation, acetylation, 
phosphorylation, ubiquitinylation and sumoylation (17, 18). By changing the conformation 
and the density of the DNA, epigenetic mechanisms are important regulators of gene 
transcription machinery. Epigenetic changes occur in the context of nucleosomes. 
Nucleosomes are the fundamental units of chromatin, consisting of a 146 bp DNA region, 
which is wrapped ~1.8 times around a protein octamer 
composed of 2 times H2A, H2B, H3 and H4 histone 
proteins (19). Histones of the H1 family (also called linker 
histones) are not connected to the histone octamer itself 
but interact directly with DNA between two of these 
octamers. This interaction leads to a higher level of 
organization which is called “solenoid” helical fibres 
(30nm fibres) (20-22). Schematically the DNA formation 
can be described as a “pearl necklace” (see Figure 1). The 
amino-terminal tails of histone proteins reach out of the 
“pearls” and are targets for post-replicative modifications.  
The combination of DNA methylation and histone protein modification results in the 
formation of either euchromatin or heterochromatin. The term euchromatin characterizes 
DNA regions showing a light compactation and consequently high gene transcription level. In 
contrast to that the term heterochromatin characterizes highly packed DNA regions which 
are transcriptionally inactive.   
Figure 1 
The fundamental unit of the chromatin: the 
nucleosome. 146bp long DNA regions are 
wrapped around a histone protein 
octamer. DNA regions lying between the 
nucleosomes are called linker DNA and are 
20-60 bp long (1).  
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Recent studies suggest that DNA methylation is directly associated with certain 
modifications of histone proteins, as further discussed in section 5.1.2. The accruing 
epigenetic code of each cell is the outcome of a dynamic process, which is in general stable 
and can be inherited to following generations. Apart from its essential physiological function 
in each cell aberrant epigenetic regulation can lead to several pathologies such as cancer 
(23, 24).  
5.1.1 Histone protein modifications 
The most important histone modifications are acetylation, phosphorylation and 
methylation (25). Histone modifications affect DNA compactation in either cis-effect, 
meaning that the chromosomal structure is directly affected by the modification, or in trans-
effect leading to an inhibition of other factors, for example DNA binding proteins that causes 
change of the chromatin formation (26, 27).  
So far, histone acetylation is the best studied histone modification. During histone 
acetylation, acetyl groups (-COCH3) are transferred from the donor acetyl-CoA to lysine 
residues in the histone tail, catalyzed by enzymes of the histone acetyltransferase (HATs) 
family (28). Generally, addition of an acetyl group to a histone tail diminishes the positive 
charge of the histone octamer resulting in a weaker interaction between the negatively 
charged DNA backbone and the histone octamer what leads to reduced chromatin 
compactation. The obtained formation favors higher transcriptional activity due to higher 
accessibility of the DNA for the transcription machinery (29). The antagonists of HATs are 
histone deacetylases (HDACs) which catalyze the elimination of acetyl groups from the 
histone tails leading to a repressive chromatin structure (heterochromatin).  
Histone acetylation is a very dynamic process. Removing acetyl groups from the DNA, 
which can be undertaken within minutes leads to a conversion from actively transcribed 
DNA into inactive and densely packed DNA. On the contrary, addition of acetyl groups to the 
DNA takes longer suggesting that inhibition of gene expression can be enabled in a short 
period of time. Gene activation is a longer taking process (30). 
Besides this molecular regulation mechanism phosporylation of histone tails is important 
for regulating gene expression. Phosphate groups (-PO4) are mainly transferred to serine 
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residues within histone tail of H3 (31). Moreover, phosphorylation can not only be found 
within histone octamers but also on a conserved serine/threonine, proline, any amino acid, 
lysine/arginine (S/T-P-X- K/R) motif within the N-terminus of H1. In this way the direct 
interaction of H1 with the DNA is inhibited and the chromatin fiber is destabilized (32). The 
transfer of the phosphate group is catalyzed by enzymes of the kinase family.  
Another important histone modification is mainly found on lysine residues: histone 
methylation. The transfer of the methyl group (-CH3) is catalyzed by enzymes of the protein 
histone lysine methyltransferase. Histone methylation occurs within histone H3 (K4, K9, K27, 
K36, K79) and on one lysine residue within histone H4 (K20). Depending on the position of 
the methyl group this modification can operate either as a transcription activator or inhibitor 
by altering density of the chromatin compactation. While methylation at H3-K9 leads to 
transcriptional repression, methylation at H3-K4 is associated with transcriptional activation 
(33).  
 These modifications can affect each other in a synergistic or antagonistic way and are 
not independent transcription alteration factors. Thus, activation or inhibition of gene 
expression results from the sum of epigenetic modifications, the histone-code (34, 35).   
5.1.2  DNA methylation 
 Apart from modifications of histone proteins which are involved in the regulation of 
gene expression (see section 5.1.1) DNA itself can be target for post-replicative modification 
by DNA methylation, thus, affecting the transcriptional activity of specific genes. DNA 
methylation regulates gene expression either directly or by influencing the modification of 
the histone proteins which influences gene expression (36).  
Two different mechanisms for DNA methylation are known. De novo methylation by 
adding a methyl group to a so far unmethylated cytosine and maintenance methylation 
which describes the copying process of pre-existing methylation patterns from the mother 
strand to the newly synthesized DNA strand after replication. Maintenance methylation 
facilitates inheritance of the DNA methylation patterns during cell division (37).  
Proteins specifically recognizing different states of cytosine modification are necessary to 
fulfill these different tasks. Proteins responsible for de novo methylation bind unmethylated 
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cytosines and enzymes necessary for maintenance methylation have to bind specifically to 
hemimethylated DNA sections. Figure 2 shows these two mechanisms.  
 
Figure 2 
Illustration of the different methylation processes. De novo methylation is the introduction of methyl groups at previously 
unmethylated cytosines. Maintenance methylation ensures conservation of the methylation pattern during replication by 
copying the methylation pattern from the mother strand to the daughter stand (38). 
5.1.2.1 CpG islands  
In mammalian somatic cells cytosines in cytosine-guanine dinucletides (CpG) are the 
targets for DNA methylation (39). CpG dinucleotides are widely under re-presented in the 
whole genome. Only in some regions of the genome the estimated CpG ratio and even 
higher ratios can be found (40, 41). These regions are called CpG islands and are in general 
0.5-4 kb in length (42, 43). Methylated CpGs are in most cases localized at transcriptionally 
inactive or even heterochromatin sections of the genome suggesting that methylation of a 
CpG island is correlated with compactation of the DNA (44). Computer analyses predicted 
that 28.890 CpG islands are present in a mammalian genome (45, 46). But 70%-80% of CpG 
dinucleotides in the mammalian genome are methylated (47). However, in 5’ regions of 
approximately 60% of all genes CpG islands can be found (48). Thereby, CpG islands can 
overlap with the promoter region and can extend even into the exonic regions. With the 
Background   
 
13 Valerie Babinsky 0405551 
 
exception of X-chromosomally inactivated genes, imprinted genes and tissue specifically 
expressed genes CpG islands in 5’ regions of genes are generally unmethylated (49).  
5.1.2.2 CpG methylation 
The transfer of a methyl group (-CH3) from a universal methyl group donor called S-
Adenosyl-L-Methionin (SAM or AdoMet) to a 5’ carbon of cytosine bases is called DNA 
methylation (50). SAM is derived in a metabolic pathway called “one-carbon cycle” from the 
source material amino acid L-methionine. The amino acid like molecule is an important 
methyl group donor in many enzymatic pathways such as synthesis of hormones, 
neurotransmitters, nucleic acids, proteins, and phospholipids (51). The methyl group is 
bound to a charged sulfate atom and is then highly reactive towards polarisable nucleophiles 
such as N, O and S as well as towards activated C atoms (like carbanions).  
The covalent attachment of the methyl group is catalyzed by enzymes of the DNA 
methyltransferase (DNMT) family (52). These enzymes have the ability to change the 
conformation of DNA to get access to the cytosine bases. SAM is inserted into the pocket of 
the enzyme and positioned by a methionin rich loop within the pocket increasing the affinity 
of the enzyme to the DNA 900-fold. By flipping the target cytosine 180° out of the helix the 
base looses the stacking interaction with its neighboring base and can also fit into the pocket 
of the active site of the enzyme (53). Additionally, the flipping mechanism minimizes the 
distance between the methyl group donor and methyl group acceptor (54). This change of 
conformation allows interactions between the catalytic side Cys81 of the enzyme and the 
cytosine. By interaction of the sulfur of Cys81 of the enzyme with C6 of the cytosine a 
covalent intermediate is formed and the methylation process becomes possible. 5-methyl-
2’-deoxycytidine is formed by the attack of the formed carbanion to the methyl group of 
SAM. After the methyl transfer is performed a proton is abstracted from C5 of the cytosine 
base followed by a beta-elimination of enzyme-DNA educt and product dissociation (53, 55). 
Chemical structure formula of the educt and the product are shown in Figure 3. 
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Figure 3  
Transfer of a methyl group from a universal methyl group donor to a cytosine base is called DNA methylation;                       
modified from  (56) 
 
5.1.2.3 DNA methyltransferases  
Transfer of methyl groups from a universal donor to DNA is catalyzed by enzymes of the 
DNMT family (52). In mammalian cells three members of the DNMT family are known: 
DNMT1, DNMT2 and DNMT3. DNMT1 measures 193.5 kD and has the ability to interact with 
methylated as well as with unmethylated cytosines catalyzing both de novo methylation and 
maintenance methylation. However, DNMT1 shows in general 5 to 30-fold preference for 
hemimethylated DNA stands determining maintenance methylation during replication as its 
main function (57, 58).  
Structural analyses of DNMT1 revealed that the C-terminus contains the catalytic 
domain, which shows a close relation to bacterial restriction methyltransferase than to other 
DNA methyltransferases in mammalians (59). Multiple domains important for different 
functions specific for eukaryotes are located near the N-terminus of DNMT1. For example 
import into the nucleus, targeting to the transcription loci or coordination and methylation 
during S-phase are regulated by this region of the protein. DNMT1 is essential for imprinted 
genes (49, 50). During the process of maintaining the methylation pattern in the newly 
synthesized DNA strand, DNMT1 can interact with a variety of co-proteins elevating the 
efficiency and the specificity of the enzyme.   
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DNMT1 is co-localized to the region of replication (60). By binding to “proliferative cell 
nuclear antigen” (PCNA) the ability to form a physical interaction to the DNA is heightened 
and the maintenance methylation capacity of DNMT1 is increased (61). The binding of the 
co-protein has positive impact on the methylation frequency but studies demonstrated that 
its presence is not absolutely necessary for the process of maintenance methylation.   
For a long time DNMT1 has been the only DNA methyltransferase identified in mammals. 
In 1998 expressed sequence tag (EST) database searches revealed another DNA 
methyltransferase called DNMT2 (62). Studies showed that knockout mice for DNMT2 had 
neither deficiency in DNA methylation in embryonic stem cell nor was DNA methylation of 
newly integrated retroviral DNA impossible what raised the question of the presence of 
methylation catalyzing activity within this protein (63). The physiological function is so far 
not completely understood. Only three facts were determined: Firstly, DNMT2 shows 
structures known from other DNA methylating enzymes. Secondly, DNMT2 has a DNA 
binding domain and thirdly, DNMT2 only comprises a catalytic domain but no regulatory 
domain (64). These findings allow the hypothesis that DNMT2 is a member of the 
methyltransferanse family but research is far from understanding completely its physiologic 
function. Well conserved DNMT2 homologues were found in plants, vertebrates, D. 
Melanogaster and S. pompe proposing DNMT2 to be the most conserved member of the 
DNMT family throughout the phylogenetic tree (65).  
Afterwards, members of the DNMT3 enzyme family were identified in the EST data base 
(DNMT3a, DNMT3b and DNMT3L) (66). DNMT3a and DNMT3b are essential for de novo 
methylation in mammals during development but can also lead to aberrant methylation 
patterns in cancer cells (67). In general DNMT3a and DNMT3b are highly expressed in 
undifferentiated embryonic stem cells but show minimal expression in differentiated 
somatic cells (68). DNMT3L is a protein related to DNMT3a and DNMT3b. No enzymatic 
activity can be found within DNMT3L, however by physically interaction with the enzymes 
DNMT3a and DNMT3b it modulates the catalytic activity of these proteins (69). Schematic 
structures of the DNMT family members are depictured in Figure 4.  
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Figure 4  
Known members of the DNMT super-family are summarized. DNMT1 is essential for maintenance methylation. Function of 
DNMT2 is so far unknown. DNMT3A andDNMT3B are essential for de novo methylation. DNMT3L is a co-factor protein for 
DNMT3A and DNMT3B.   
 
5.2 Effects of DNA methylation on gene transcription 
DNA methylation can alter gene expression either directly or indirectly. Direct inhibition 
of gene transcription can be found in genes which show a tissue specific gene expression 
pattern. The methyl group prevents the binding of transcription factors like MLTF, E2F or 
CREB due to steric interaction with the DNA binding proteins (70, 71). Iguchi-Ariga et al. (72) 
showed that a single methyl group on one CpG site within the CRE binding domain directly 
prevents the binding of the transcription factor CREB and inhibits the transcription. Apart 
from these cis-acting inhibition mechanisms, trans-acting ones are known. SP1 binding site 
for example attracts apart from SP1 other proteins, which make DNA methylation impossible 
(73). This “protection” can often be found in housekeeping genes (see Figure 5).   
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Figure 5  
Promoter region with CpG island, without protection methylation spreads over the whole CpG island. SP1 binding site 
attracts “protection” proteins making methylation spreading over CpG island impossible; modified from (73) 
 
For the indirect inhibition two protein super-families are needed: Kaiso like proteins and 
Methyl-CpG binding proteins (MBD) (74). 
Kaiso like proteins interact physically with methylated cytosines via multiple zinc finger 
motives (75). A recent report showed that two proteins of this super-family, ZBTB4 and 
ZBTB38 bind to single methylated CpGs and inhibit transcription (76).  
Methyl-CpG-binding protein 2 (MeCP2) was the first identified protein of the MBD family 
(77). It contains a N-terminal methyl-CpG binding domain (MBD) and a C-terminal 
transcriptional repression domain (TRD) (78, 79). Immunoprecipitation experiments revealed 
that TRD interacts with Sin3A (a transcriptional co-repressor) in mammals, which is part of a 
large inhibitory complex also comprising histone deacetylases HDAC1 and HDAC2 (80). 
Similarly HDAC1 and HDAC2 are attracted to DNA, chromatin formation becomes more 
condensed by eliminating acetyl groups and the expression of the affected gene is reduced 
(Figure 6) (80). Six members of the MBD family are known so far: MeCP1 (74), MeCP2 (81), 
MBD1 (82), MBD2 (83), MBD3 (83) and MBD4 (84). All these proteins show a high 
conservation throughout the vertebrates. Apart from the other family members MBD3 
shows a mutation of its methyl-cytosine binding domain, preventing selective recognition of 
methylated DNA (85). However, MBD3 is of importance for gene expression regulation by 
recruiting co-repressor complexes to methylated DNA (86). The presence of MBD3 in mice 
cells was related with a higher frequency of adenocarcinomas suggesting that this protein 
plays an important role in carcinogenesis (87).  
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Figure 6  
Methylated cytosines are recognized by MBD proteins. These interact with mSin3A, which is part of a great complex 
comprising HDAC. Contact between methylated DNA and HDACs is achieved; the chromatin formation tightens up. 
Modified from (36) 
 
5.3 Epigenetic changes are reversible  
Epigenetic changes are dynamic and reversible processes. Epigenetics takes part in 
facilitating the wide diversity of cell types (88). Besides, its physiologic function epigenetic 
changes can appear aberrantly during aging and development causing expression 
disequilibrium what may lead to pathologies (64, 65). 
Research revealed that epigenetic changes can be controlled by intrinsic signals but also 
by external induction (89, 90). In vitro DNA methylation or histone protein modification can 
be pharmacologically reversed (91). Often used DNA de-methylating agents are 5-aza-2'-
deoxycytidine (Aza-dC) and 5-azacytidine (5-AzaCR). Both of them are base analogous for 
deoxycytidine. Due to a modification on position 5 in the pyrimidine ring methyl groups can 
no longer be added, making maintenance of the DNA methylation pattern impossible (92). In 
these analogues the 5’ carbon is replaced by nitrogen (see Figure 7 and Figure 8). Before 
incorporation into DNA or RNA the base analogues are phosphorylated to form the 
nucleoside triphosphate (93). 
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Figure 7  
Structural formula of 2’-deoxycytidine and of frequently used base analogous 5-aza-2’-deoxycytidene and 5-azacytidine. 
Modification of the 5’ position in the pyrimidine ring inhibits maintenance methylation.   
 
Aza-dC is only incorporated into DNA but not into RNA and shows a higher cytotoxicity 
than 5-AzaCR. Incorporated in DNA the analogue binds covalently to different members of 
the DNMT family by forming unresolved thioether bond at the C6 (94). Due to this depletion 
of DNMT it is unavailable for maintenance methylation resulting in significant demethylation 
after repeated replication (95).  
It has been shown that expression of several tumor suppressor genes (TSG) which are 
often inhibited by DNA methylation in cancer cells (e.g. p16, RASSF1 and CDH1) can be 
restored by adding Aza-dC or 5-AzaCR in vitro (65-67). In clinical trials the anti-cancer 
function of Aza-dC was shown in acute myeloid leukemia (AML), myelodysplastic syndrome 
(MDS), chronic myelocytic leukemia (CML) and hemoglobinopathies, however its efficacy in 
solid tumors is poor (96).  
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Figure 8 
Base analogues are incorporated into DNA forming an unresolved thioether bond with DNMTs leading to unavailability of 
DNMTs. Maintenance of the methylation is impossible in the consequent duplication steps.   
 
Besides DNA methylation also histone protein modifications can be induced or reversed 
by epigenetically active drugs. A commonly used one is trichostatin A (TSA) which inhibits 
the histone protein deacetylation (for the chemical structure formula see Figure 9) (97). TSA 
is an hydroxamic acid and the best studied histone deacetylase inhibitor (98). It forms a 
complex with a zinc atom at the base of the catalytic site of histone deacetylases and 
prevents interaction between the enzyme and the substrate (99). Thus, TSA inhibits removal 
of the acetyl groups resulting in active gene expression (100). 
Pharmacologic manipulation with TSA leads to limited tumor cell growth in vivo with 
little or no toxicity (101). In addition histone deacetylase inhibiters block angiogenesis in 
vitro and in vivo due to normalization of the acetylation pattern of the TSG p53 and VHL. 
Additional studies are necessary to identify a potential impact of TSA for cancer therapy.  
 
Figure 9  
Chemical structure of the commonly used histone protein deacetylation agent TSA. By blocking the histone deacetylases 
TSA prevents the de-acetylation and thereby keeps the gene expression active. 
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DNA methylation and histone protein modifications strongly influence each other. Due to 
this close relation synergistic effects of DNMT inhibitors and HDAC inhibitors have been 
identified (102).  
5.4 Lung cancer 
Lung cancer is the number one cause of cancer deaths, killing one million people 
worldwide each year. Smoking is one of the leading causes of premature death and can be 
set in relation to 85% of all diagnosed lung cancer cases making tobacco smoke to the 
number one carcinogen for the lung (103, 104). Moreover length and heaviness of the 
smoking habit can be set in relation to probability of coming down with lung cancer. For a 
long life smoker the probability for lung cancer is 20-fold higher than the probability for a 
never smoker. The lung cancer risk after stopping smoking diminishes but only after 5 years 
of non-smoking and is never as low as the risk of a never smoker. However not only 
mainstream smoke but also second-hand smoke is known as pulmonary carcinogen (105).  
Over 60 carcinogens can be found in tobacco smoke, which induce tumor genesis in vivo 
(106). Nicotine is not carcinogen itself but interacts with pathways which deregulate cancer 
related genes (107, 108). Nicotine interacts for example with ERK and PI3-K/mTOR pathways 
inducing fibronectin and promoting proliferation of NSCLC. Additionally, it is an addictive 
drug thus being the reason why people go on smoking (109). The best analyzed tobacco 
carcinogens are members of the polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines 
and aromatic amines families. Recent reports determined tobacco-specific N-nitrosamines 
(TSNAs) and PAHs as the most harmful carcinogens in tobacco smoke (110). PAHs are formed 
due to the incomplete pyrolysis of tobacco leaves (111). TSNA derive from nicotine and 
related tobacco alkaloids (112). Three TSNAs, namely N-nitrosonornicotine (NNN), 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL), show high tumor inductive capacity in mice, rats and hamsters 
(113) (chemical structure formula depictured in Figure 10). They are all formed by 
nitrosation (N=O group is added) of secondary and tertiary amines and contain the 
functional group N-N=O. 
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In addition to the direct carcinogenicity in tobacco smoke smoking favors malignant 
transformation by acting as direct mucus irritant and inducing inflammation which leads to 
generation of free oxygen radicals (114).  
 
 
Figure 10  
Structural formula of most important carcinogens derived from tobacco smoke; N-nitrosonornicotine (NNN), 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL); (115) 
 
 
For a long time lung cancer was a men’s disease. However, in recent years a decrease in 
the incidence of lung cancer in men, but an increase of the incidence in women was 
observed. (116).  
Lung cancer can be distinguished into two major types: small cell lung cancers (SCLC) and 
non-small cell lung cancers (NSCLC) (117). Thereby, 85% of all lung cancer patients suffer 
from NSCLCs (118). Furthermore NSCLCs are divided into three subtypes according their 
histological properties: adenocarcinomas, squamous cell carcinomas and large cell 
carcinomas (119). Lung cancer is very often a deadly disease with 5-year survival rates of 
only 14% (120). 
Lung cancer is a multistep mechanism of changes in the genetic and the epigenetic code 
caused by exposure to carcinogens, like tobacco smoke or other harmful substances, over a 
long period of time (121). In this disease, like in many others an early prognosis augments 
the cure-chance drastically. Diagnostic techniques like spiral computed tomography, sputum 
cytology, histopathology or tumor-node-metastasis classification often failed to allow a 
sensitive diagnose. In recent years great efforts were taken to identify molecular changes 
relevant for the pathogenesis of NSCLCs like K-ras, p53 mutation status and microsatellite 
instability (122, 123). Furthermore DNA methylation was found to be of tremendous 
importance for development of NSCLCs (124).  
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5.4.1 DNA methylation as molecular biomarker in NSCLC 
Epigenetics is one of the regulation mechanisms for gene expression which can be 
altered during carcinogenesis (125). In this work we focused on a part of epigenetics, the 
DNA methylation. Aberrations in DNA methylation patterns can occur early in carcinogenesis 
and can be found already in pre-carcinogenous lesions in the lung (126). Several genes 
including p16, RASSF1A, APC, RARß-2, CDH1, CDH13, DAPK, and MGMT were found to be 
frequently methylated in primary NSCLCs (127-135). All these genes were found to be 
associated to cancer related pathways such as apoptosis, cell proliferation or DNA repair.    
Recently, genome-wide approaches for DNA methylation analysis were developed.   
5.5 DNA methylation analyses 
Different approaches have been developed to analyze DNA methylation: 1) Methylation 
sensitive restriction enzymes (136). 2) Methylation-specific polymerase chain reaction 
(MSP), 3) combined bisulfite restriction analyses (COBRA) and 4) bisulfite genomic 
sequencing. Due to the great number of possible targets for methylation in the genome the 
need for genome-wide techniques became apparent. Techniques, like the methylated DNA 
immunoprecipitation combined with microarray analyses (MeDIP-chip) or approaches with 
epigenetically active drugs combined with gene expression microarrays which allow the 
analysis of ~29.000 genes at a time, has become available over the last years (124).  
5.5.1 Sodium bisulfite treatment  
Most of the PCR based approaches for DNA methylation analysis are only applicable for 
sodium bisulfite treated DNA. During common PCR reactions methylation signals are lost, 
due to the fact that primers cannot distinguish between methylated and unmethylated 
cytosine. However, sodium bisulfite treatment makes distinguishing between methylated 
and unmethylated alleles possible (137). This approach was first identified in 1970 by 
Hayatsu et al. (138). Sodium bisulfite treatment can be divided into four steps: denaturation, 
addition of sodium bisulfite to the double bond between the position 5-6 of the cytosine, 
deamination and desulphonation by subsequent alkali treatment. During that treatment 
Background   
 
24 Valerie Babinsky 0405551 
 
unmethylated cytosines are deaminated to uraciles. In the next replication step uraciles are 
replicated as thymines. Due to the fact that the rate of deamination of unmethylated 
cytosines to uraciles is much higher than the deamination of methylated cytosines to 
thymines all remaining cytosines after the treatment are derived from methylated cytosine. 
Performed under proper condition (pH 4.8-5.8, 3.0-4.0 M sodium bisulfite concentration and 
60°C temperature) the conversion rate of unmethylated cytosines to uraciles is 99% (137, 
139-141).  
A graphic summary of the process is provided in Figure 11. In ds DNA the base pairing 
locks the base cytosine in the inactive anti conformation. Single strand DNA provides the 
required syn conformation. Only in the syn conformation interaction between the position 6 
of the pyrimidine ring and sodium bisulfate is possible (142, 143). Thus, denaturation of the 
template DNA is necessary. 
 
   
Figure 11 
Incubation of DNA with sodium bisulfite requires DNA bases in syn conformation. Unmethylated cytosines are converted to 
uraciles in four steps.  Uraciles are converted to thymines in the consequent PCR step. Only methylated cytosines remain 
cytosines after sodium bisulfite treatment. Modified from (144) 
 
5.5.2 PCR based techniques for analyzing DNA methylation  
Two different strategies are used for PCR based DNA methylation analysis. First, use of 
methylation-independent PCR primers (MIP). For this analysis only one primer set is 
designed which binds to both the methylated and the unmethylated allele. Due to the fact 
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that unmethylated sequences relatively poor of CG dinucleotides are amplified in a higher 
rate than methylated ones a PCR bias is only preventable by designing primers without any 
CG dinucleotides. An example for this approach is the COBRA technique. After bisulfite 
treatment of genomic DNA amplification with MIP primers is performed. Due to the bisulfite 
treatment new methylation-dependent restriction sites arise and methylation-depending 
retention of pre-existing sites can occur (145). If a cytosine is methylated it remains a 
cytosine during the sodium bisulfite treatment, an unmethylated cytosine is converted into a 
thymine and the restriction site is lost or a new one is formed (146).  Subsequently, digestion 
with restriction enzymes specific for sites containing CpGs makes the distinction between 
methylated and unmethylated regions possible (147). The results are visualized with PAGE 
gel equipment.     
Second, use of methylation-specific PCR primers (MSP) (see Figure 12). The MSP 
approach is one of the most used and most efficient techniques to analyze the methylation 
status of specific genomic regions. Genomic DNA is firstly treated with sodium bisulfite to 
allow a distinction between methylated and unmethylated alleles. Primers specific for either 
bisulfite converted methylated or bisulfite converted unmethylated region are design. The 
primer design step is the most critical one within this technique. It has to be guaranteed that 
primers only form duplexes with the region of interest but not unspecifically with other 
regions or other primers. The primers have to contain as many CpGs as possible, minimally 2 
CpGs and the CpGs have to be as near as possible at the 3’ end of the primer. The PCR 
program has to be as stringent as possible, which means high annealing temperatures and 
low cycle numbers to avoid false positive results (148). During PCR with primers specific for 
the bisulfite converted methylated allele only DNA with methylated primer-binding site can 
be amplified and visualized by a gel-electrophoresis equipment.   
MSP is a fast and precise analysis which the analyses can be performed in a short time 
period. In addition only a small amount of DNA is needed. However, the MSP assay is only a 
qualitative but not a quantitative analysis. 
To perform quantitative analyses fluorescence-based, quantitative real-time PCR 
approaches can be used. By intercalation of the fluorescent dye into the newly synthesized 
ds DNA the amount of produced DNA can be measured after every cycle of elongation (149). 
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Figure 12  
Schematic description of a MSP work protocol. Firstly, genomic DNA samples are treated with sodium bisulfite to convert 
unmethylated cytosines into thymines. Secondly, primers are designed for the methylated as well as for the unmethylated 
allele. By PCR amplification the methylation status of one specific gene is identified. 
 
5.5.3 DNA methylation analysis on a whole genome level     
Computer analyses revealed that approximately 29.000 CpGs are present in the human 
genome (46).  On average 600 of these CpG islands are aberrantly methylated in a tumor 
(15). To analyze this huge amount of CpG islands without time consuming single loci 
determination of methylation patterns, whole genome approaches have been established 
during the last years. The first whole genome approach was restriction landmark genomic 
scanning (RLGS). With RLGS Dai et al. (150) identified 11 genes with different methylation 
patterns in lung tumor samples compared to corresponding non-malignant lung samples.  
 As mentioned in section 5.3 DNA methylation is reversible in vivo and in vitro. This 
fact can be used for whole genome approaches. By treatment of cells with DNMT inhibiting 
drugs like Aza-dC or 5-AzaC DNA methylation is reversible. Due to interaction between DNA 
methylation and histone deacetylation, a synergistic effect between DNMT inhibitors and 
HDAC inhibitors was observed in vitro (151, 152). Gene expression patterns of cells which 
are treated with demethylating and histone deacetylation inhibiting drugs and patterns of 
untreated cells are compared by expression microarray analyses. Expression of methylated 
genes is up-regulated by drug treatment compared to untreated cells (120, 153). Thus, genes 
Background   
 
27 Valerie Babinsky 0405551 
 
that are not expressed before treatment and expressed after treatment are genes of interest 
for further gene-specific methylation analyses. Using this approach Shames et al. (154) 
identified several unknown targets for aberrant methylation (e.g. BNC1, LOX) in NSCLC cell 
lines. The major disadvantage of this approach is that it can only be applied in vitro. It is 
known that methylation can accumulate in cell culture (120). Thus, results obtained from 
this approach have to be approved in primary tissue samples to be able to exclude artifacts 
caused by in vitro culturing. Additionally, treatment with DNMT inhibitors and HDAC 
inhibitors activates several stress responses in treated cells. Verification of the obtained 
results is an important step to exclude false positives from the results. 
Recently, a new method to detect genome-wide DNA methylation has been described by 
Weber et al. (155). Based on combination of immunoprecipitation and microarray analyses 
the methylation status of all annotated genes can be identified. Genomic DNA is fragmented 
by sonication or restriction enzyme digestion obtaining fragments with a length of optimally 
between 200bp and 800bp. With an antibody specific for 5-methylcytosine methylated DNA 
fragments are enriched in an immunoprecipitated sample (IP) and separated from the 
unmethylated fragments. The IP sample is hybridized to a microarray chip together with a 
control sample containing the whole genomic DNA (Input). By labeling IP and Input with 
different fluorescent dyes the two samples will be compared. This new technique allows an 
unbiased detection of DNA methylation on a whole genome level. Using this approach 
Weber et al. (155) identified a great variety of genes which are targets for aberrant 
methylation in transformed cells like FOF1, PAX6, TGFB2 or ADAM12.   
5.6 DNA methylation and its impact on NSCLC 
For a long time the origin of cancer has been put down to mutations and other 
alterations in the genomic sequence. However, during the last decade it became apparent 
that NSCLC arises from a multi step process implying aberration not only in the genetic but 
also in the epigenetic code (156). Particularly aberrations in DNA methylation patterns were 
found in NSCLCs. Promoter hypermethylation of TSGs occurs throughout the tumor genesis 
and can even be found in pre-carcinogenous lesions suggesting hypermethylation of certain 
genes to be one of the earliest hits in the pathogenesis of a tumor (157).  
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 Methylation of certain genes can be detected in blood samples, in exfoliative 
material of the aero digestive tract epithelium and in sputum from lung cancer patients 
(120). It has been hypothesized that samples which are obtained through non invasive or 
minimal invasive methods could be of use for predicting possible disease recurrence after 
surgery or even an early detection of lung cancer (11, 158). Clinical studies on this subject 
are necessary. Using serum samples for analyses of the methylation status is controversial, 
since methylation frequency of genes detected in serum samples is lower than frequencies 
of methylation of the same genes analyzed in the corresponding primary lung tumor tissue. 
However, only genes that are methylated in the primary tumor show methylation in the 
serum sample (9). By contrast, it has been reported that sputum samples seem to be an 
adequate possibility (13).  
During the last years a respectable number of genes could be identified which show 
tumor-specific methylation pattern. For example the methylation status of RASSF1A, p16, 
CDH1, DAPK, APC, RARβ-2 and MGMT was intensively studied revealing that these genes 
undergo changes in their methylation pattern during the pathogenesis of NSCLC. TSGs which 
are methylated in tumor samples were often associated to pathways important for cell cycle 
regulation (e.g. p16 and RASSF1A), regulation of cell adhesion (e.g. CDH1), regulation of 
growth (e.g. APC and RARβ-2) regulation of apoptosis (e.g. DAPK) or DNA repair (e.g. MGMT) 
(128-131).  
Toyooka et al. (159) showed that methylation of APC, CDH13 and p16 differ between 
NSCLCs samples and neuroendocrine tumors showing a higher methylation rate in NSCLCs. 
RASSF1A on the contrary showed higher methylation frequency in neuroendocrine tumors. 
These data suggest that DNA methylation is tumor type-specific. Furthermore, it has been 
observed that aberration of the methylation pattern is even specific for the two main 
subtypes of NSCLC, adenocarcinomas and squamous cell carcinomas. P16 for example is 
more frequently methylated in squamous cell carcinomas than in adenocarcinomas, whereas 
methylation of APC and CDH13 occurs with a higher frequency in adenocarcinomas (160, 
161). 
The methylation frequency of p16 is not only cancer type specific but can also be set in 
relation to the smoking habit of patients suffering from this cancer type. In general, 
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exposure to tobacco-related carcinogens increases the methylation frequency of p16 which 
can even be found in non-carcinogenous lung tissue samples of ever smokers. These findings 
suggest that changes in the p16 methylation pattern are one of the earliest events in the 
pathology of NSCLC (114, 126). Comparative analyses by Belinsky et al. (162) of p16 and 
DAPK methylation revealed that changes in the methylation pattern occurring due to 
exposure to tobacco smoke persists for a long time even after stopping smoking.  
Elevation of methylation frequency in cells after exposure to tobacco smoke can be due 
to enrichment of DNMT1. By working in vitro with immortalized bronchial epithelial cells 
Damiani et al. (163) showed that elevation of DNMT1 level after benzo(a)pyrene-diolepoxide 
1 and/or methylnitrosurea exposure maybe of two reasons. Firstly, DNMT1 expression is 
elevated after tobacco-smoke induction. Secondly, degradation of DNMT1 is inhibited due to 
over expression of the spindle check point protein MAD2.      
Several studies suggested the methylation pattern is of prognostic relevance (164-166). 
DAPK methylation was found to be associated with a poor overall and disease-specific 
survival, due to a higher invasiveness of tumors after inactivation of DAPK (164). 
Interestingly, CDH1 methylation correlated with a higher overall survival, probably due to a 
highly dynamic methylation and demethylation process during invasion of tumor cells into 
new tissues (167).  
Disease recurrence occurs frequently in NSCLC patients. Brock et al. (168) analyzed the 
methylation pattern of genes including p16, MGMT, DAPK, RASSF1A, CDH13, APC and ASC 
and compared the results with clinico-pathological findings of the patients. Methylation of 
p16, RASSF1A, CDH13 and APC in the primary tumors and corresponding tumor-negative 
lymph nodes was found to be associated with a high probability of recurrence. These 
findings suggest that methylation analyses might be helpful determining risk assessment for 
disease recurrence in NSCLC patients.  
Moreover, several studies revealed that due to the reversibility of DNA methylation it is a 
potential target for anti-cancer therapy. Treatment with DNMT1 inhibiting agents such as 
Aza-dC or 5-AzaC in addition to HDAC inhibitors showed in vitro anti-carcinogenic attributes. 
Thus, by methylation inhibited TSGs can be reactivated and their expression level can be 
restored.  5-AzaC is used clinically for the treatment of patients suffering from certain types 
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leukemia and myelodysplastic syndromes (93, 169). However, currently 5-AzaC is not used 
for solid tumors. Juergens et al. (170) reported some benefits for NSCLC patients treated 
with 5-AzaC in a phase-II trial.  
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6 MATERIAL AND METHODS  
6.1 Cell culture 
Materials:  
Growth Medium RPMI 
1640+Glutamax 
(Gibco; #145238) 
Trypsin EDTA  (Gibco; #197812) 
FCS  (Gibco; #179822) 
Refobacin  (Merck; #112214) 
  
It is necessary to work in a sterile surrounding to avoid contamination. Thus, the work 
had always to be performed in sterile bench with gloves. Before starting the work the sterile 
bench had to be cleaned, the UV-light had to be turned on for approximately 30 minutes and 
the cell culture medium had to be prepared. Therefore, 50ml FCS and 40mg of the antibiotic 
refobacin were added to 500ml growth medium. The growth medium can be stored at 4°C 
and had to be warmed up previous to each use (37°C). Cells were grown in cell culture flasks 
(BD Falcon, 750ml, and straight neck).  
First of all, cells had to be washed. The old medium was decanted, then 5ml trypsin were 
added and incubated until cells start to detach from the flask ground. Then 20ml medium 
were added to stop the detachment reaction. Cells were washed of the surface and 
transferred into a 50ml falcon tube. Afterwards, cells were centrifuged for 5 minutes at 
2000rpm, the medium was decanted and 20ml fresh growth medium were added to start a 
second washing step. Then cells were ready for DNA extraction-, cell passaging- or cell 
freezing-process.  
6.1.1 Cell passaging 
After the washing step cells were resuspended in new growth medium in the correct 
concentration to allow an optimal growth and were transferred to a new culture flask. For a 
proper growth, lung adenocarcinoma cell lines A549, NCI-H1993, NCI-2073 and NHBE cells 
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were incubated at 37°C, 5 % CO2 and 96% humidity in an incubator. Growth medium was 
changed every 3-4 days. Cells were grown to 80% confluence before the cells were split the 
next time.  
6.1.2 Cell freezing  
Materials:  
Freezing Medium:  Growth medium + 5% DMSO (Gibco; #145238) 
 Cryotubes (NUNC) 
 
At a proper confluence of about 80%, cells were washed, resuspended in 3ml freezing 
medium and aliquots were made in 2ml cryotubes. Afterwards cells were stored in a cell-
freezing box (filled with methanol to allow a slow freezing process of 1°C per hour) at -80°C 
over night and then they were stored at -195°C in liquid nitrogen.     
6.1.3 Cell de-freezing 
Cryotubes were heated at 37°C until the ice was gone. As soon as cells and the medium 
were defrosted the freezing medium was toxic for cells, so the following steps had to be 
performed as fast as possible. Immediately after the ice was completely melted, the cells 
had to be washed with 15ml growth medium. The medium was decanted and cells were 
resuspended in 5ml growth medium and transferred into a new culture flask for the growth 
process in the incubator. After 24 hours the start of the cell growth was controlled. If cells 
started to grow, the medium had to be changed and cells were bred until the needed 
confluence was reached. 
6.1.4 Incubation of cells with 5-aza-2’-deoxycytidine 
Materials:  
5-aza-2’-deoxycytidine min. 95% (Sigma Aldrich; #A3656) 
 
At the beginning a stock solution was made out of 5mg Aza-dC and 250µl 1xPBS and 
then 20µl aliquots of this solution were stored at -80°C. Before starting the Aza-dC 
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incubation one aliquot was defrosted and 180µl growth medium was added.  5x106 cells 
were grown in a 175cm2 cell culture flask. From the 200µl solution 25µl were again diluted 
with 25ml growth medium and after that they were added to cells. Due to instability of the 
cytosine-analogue in the growth medium 25µl of Aza-dC dilution had to be added every day 
for the duration of four days. If necessary the growth medium was changed and cells were 
split. After the four day incubation period cells were bred in a medium without Aza-dC for 
two or three days so that they regenerate and then RNA could be extracted (see 6.2.2) 
6.2 Nucleic acid isolation   
6.2.1 Isolation of genomic DNA  
Materials:  
 PK-buffer (for ingredients see 6.6)  
 Phenol S/P saturated (Amresco; #K168-400) 
 Isoamyl-alcohol  (Sigma-Aldrich; #C549-10T) 
 Chloroform (Sigma-Aldrich; #C-5312) 
 Sodium Acetate (Sigma-Aldrich; #S9513) 
 EtOH (abs.)   (VWR; #20821.310) 
 cell scraper  (Falcon) 
 
DNA was isolated from cell lines as well as from primary lung tumor tissue samples and 
corresponding non-malignant lung tissue samples using standard phenol/chloroform 
extraction.  
Cells were bred in the culture medium until the flask showed 80% confluence. Then cells 
were scratched from the surface with a cell scraper (Falcon), transferred to a 1.5ml tube and 
incubated over night with 800μl PK-buffer at 55°C.  
The tissue samples were shredded in liquid nitrogen with the help of a mortar. Small 
tissue fragments were transferred into a 1.5ml tube containing 800μl PK-buffer and 
incubated over night at 55°C. The consequent steps can be performed for cell material 
obtained from cell culture as well as from primary tumor samples. On the next day the 
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samples were centrifuged to collect the liquids from the cap of the tube. The cell/buffer 
solution was transferred to two 2ml Phase Lock Gel Light tube, 400μl phenol were added to 
each tube and after short incubation the samples were centrifuged for 5 minutes at 
14000rpm. Through this step proteins were separated from DNA. Two phases were visible 
after the centrifugation. Due to the polar negatively charge of DNA, DNA was solved in the 
aquatic phase (the upper one). This one was decanted after the centrifugation step and 
transferred into a new 2ml Phase Lock Gel Light tube. To increase the purity of DNA an 
additional phenol extraction step was performed. Again after centrifugation the upper phase 
was transferred to a new 2ml Phase Lock Gel Light tube, 480μl chloroform as well as 20μl 
isoamyl-alcohol were added and the sample was again mixed and centrifuged for 5 minutes 
at 14000 rpm. After taking off the upper phase and transferring it to a 1.5ml tube, 1.5 
volumes of EtOH (abs.) and 50μl 3M (pH 5.2) sodium acetate were added to adjust the salt 
concentration and mixed thoroughly. The precipitated DNA became clearly visible. Finally, 
sample was put on -20°C over night. On the next day the sample was centrifuged for 15 
minutes on maximum speed (18000rpm) and at 4°C in a pre-cooled centrifuge. A pellet 
became visible. EtOH was discarded, then 600μl EtOH (70%) were added and again 
centrifuged for 10 minutes on maximum speed and at 4°C. Again EtOH (70%) was discarded, 
the sample was shortly centrifuged and the rest of EtOH (70%) was taken off with a pipette. 
The pellet was dried at 37°C for 5- 10 minutes. Depending on the size of the pellet 100-200μl 
ddH2O were added. The concentration was measured with an “Eppendorf BioPhotometer”.    
6.2.2 Isolation of total RNA 
Materials: Trizol reagent 15596-026 (Gibco; #149789) 
 Chloroform (Sigma-Aldrich; #C-5312) 
 EtOH (Merck; #1.00983.1000) 
 
Cells were transferred to a 50ml tube and washed twice. The cell pellet was resuspended 
in 1ml trizol, transferred to a 1.5ml tube and incubated for 5 minutes at room temperature. 
200µl chloroform were added for each ml trizol and the sample was mixed per hand very 
thoroughly. After 3 minutes of incubation the phases were separated from each other by 
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centrifuging the sample for 15 minutes at 11500rpm and 4°C. The upper phase was 
transferred into a new 1.5ml tube, 500µl EtOH (abs.) were added and incubated for 10 
minutes at room temperature. After centrifuging (10 minutes at 11500rpm and 4°C) the 
supernatant was removed and EtOH (70%) was added to wash the pellet. After an additional 
5 minutes centrifugation step at 7500rpm and 4°C the supernatant was decanted and the 
pellet was centrifuged briefly to be able to remove the whole amount of alcohol with a 
pipette. The pellet was dried at 37°C and then diluted in 50-200µl RNAse-free water 
depending on the size of the pellet. RNA was stored at -80 °C. 
6.2.3 RNAse treatment of extracted DNA  
To prevent interference of RNA with DNA which often causes false results DNA was 
RNAse treated. 1μl RNAse was added to DNA and incubated at 37°C for one hour. After 
incubation the probes had to be again phenol/chloroform extracted as described in 6.2.1. 
The only difference is that two hours of incubation in PK-Buffer was sufficient for digesting 
the proteins in the sample.   
6.3 Methylation-specific PCR (MSP) 
6.3.1 Sodium bisulfite treatment 
In order to perform MSP analysis DNA samples had to be treated with sodium bisulfite. 
Unmethylated cytosines but not methylated ones were converted to uraciles. Accordingly 
they were converted to thymines in the following PCR step resulting in different DNA 
sequences for methylated and unmethylated regions. Sodium bisulfite treatment was 
performed by using the “EpiTect Bisulfite Kit” (Qiagen; #59104). In brief, 1µg genomic DNA 
of each sample was treated and eluted in 40µl of the elution buffer. Each step of this 
approach was performed according to the manufacturer’s instructions.  
6.3.2 SssI CpG-methyltransferase treatment of genomic DNA 
  
Materials: 10xNEB Buffer  (Biolabs; # B7002S) 2µl 
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 diluted SAM (Biolabs; # 9003S) 2µl 
 DNA  2 µg 
 SssI methyltransferase      (Biolabs M; # M0226S) 1µl  
 add ddH2O to a final 
volume of 
  
20µl 
 
In order to make sure that the PCR worked properly, a positive and a negative control 
were added to each analysis. The negative control contained only ddH2O without any DNA 
and was required to report contaminations. The positive control was added to make sure 
that the PCR setup and the primers were working even if all analyzed samples showed a 
negative outcome. In order to produce the positive control genomic DNA was treated with 
SssI methyltransferase, an enzyme that catalyzes de novo methylation of cytosines on CpG 
sites by using the methyl group donor S-adenosyl-L-methionin (SAM). This enzyme adds a 
methyl group to each CpG in the sample DNA. 2μg of the DNA were treated with 2μl 10x NEB 
buffer, 0.5μl 200x SAM and 12U SssI methyltransferase in a total volume of 20μl. The 
samples were incubated at 37°C for one hour and consequently for 20 minutes at 65°C.  
6.3.3 Primer design 
The primer design is one of the most crucial steps during MSP. Thus, for each gene of 
interest 2-3 primer pairs were designed and tested to find the most efficient and most 
specific one. Genomic sequence of the genes of interest was obtained from Ensembl 
database (release 58) and the 5’ promoter region of each gene was used for primer design. 
Using the program “Methyl Primer Express® Software v1.0” CpG islands located in the 
promoter regions were identified and primers for the methylated and the unmethylated 
allele were designed. Criteria for CpG island detection were as follows: minimum length of 
200bp, 50% GC content and 0.60 ObsCpG/ExpCpG. In case of positive CpG island detection 
MSP primers were designed using following limitations: 100bp minimum and 250bp 
maximum length of PCR amplicon, primer length between 18bp and 22bp, Tm reaction 
between 56°C and 64°C and a minimum of 2 CpG sites per primer. Primer sequences 
designed for selected genes and the corresponding amplicon length are shown in Table 1. 
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After receiving the primers they were diluted to obtain a concentration of 1pmol/µl in 
ddH2O and accordingly a “primer pair mix” of each primer pair was prepared. That means, 
20µl of the diluted forward primer, 20µl of the diluted reverse primer, 160µl ddH2O were 
mixed (to obtain a concentration of 0,1pmol/µl) and used for the following MSP analyses.   
Using the designed primers and the prepared DNA, MSP was performed to analyze the 
methylation status of the gene of interest. The appropriate annealing temperature was 
determined by first, testing all primers with a PCR-program including an annealing condition 
at 60°C and 37 cycles. If the signal was strong MSP was repeated at a higher temperature 
and fewer cycles. If the signal was weak the temperature was decreased and the cycle-
number increased.  
 
Table 1 
Summary of oligonucleotide primer sequences used for MSP analyses and amplicon length 
Gene Primer fwd (5´-3´) Primer rev (5´-3´) Amplicon length (bp) 
ANKRD13D AGAATAAGTCGCGTTCGTTC TTTTCCGCTTAACGAAAAAA 154 
AXUD1 GTAGTCGTCGGGTTATAGTTC TCGTCAATAAAAAACTCCG 158 
ALDH1A3 TGTTTATATATAAGGCGCGC  CAAATAATCTCGCCGTTCTA  129 
BARHL2 CGATAGTTTTTTTCGTTGGTTC ACCGAACGAACGAAAATCT 174 
CD14 ATACGGTTAAGGTTTTTCGC CTCGAACGTCAATTCCTTAA 122 
CRY4D TTTGTGCGGTTTTTGTTAAC GCGATAAAAAAAACTCCGAA 171 
CUL4A CGCGGCGGCGGTTGGGTTCG GCGCCCCCCGACTTAACGAACG 217 
DLX4 AGGGGTGTTCGTGATAGATC CTCTTCTTAAATCGCCGAAC 182 
EOMES TTGTTTTATATTTGCGTGTGC AAAACACGTTTCGTTACGAA 215 
EXOSC7 CGGGATTCGGTTTCGGGTTTCG CCGCTCCTACAACCGCGACCG 120 
FOXD3 GAGGCGTATCGTTGATTTATC CAATACACGCGAAATACAAAA 176 
FOXD4L1 TCGAGAGTATATCGAGGGC CGCTAAACGTAAAACGCTTA 185 
FOXD4L3 TCGAGAGTATATCGAGGGC AATACCGCTAAACGTAAAACG 193 
GAD1 AATGAAGAACGAGGGGTATC AACCGACAACTACTCTACGCT 211 
GDNF TGGAATGGCGTATTAATTTC ACCTCGCGAACTAATTTACA 241 
GHSR TGGTATTTTATCGGGTGAGC CAAAACGCCGCTAAAAAA 170 
GHSR TGGTATTTTATCGGGTGAGC CAAAACGCCGCTAAAAAA 170 
GIPC1 CGAGAAGGATGTGTTTGTTTC TAAACCTCCAATCGCGTC 105 
GPR50 GTATCGTAGGGGAATTGTGAC ACGAAAATATCACGCGACTA 197 
HAND2 GGCGTTTAATGGTTTTTTTTC TCGATTCCCCGAATCTATAA 218 
HOXA9 GGCGTTTTCGAGTTTTTTAC CGCAAATACGTCAAAAAAAA 223 
HOXD11 GGGTTTTTACGGTAGGTTTTC GCGCCGATACATAAAAAAA 225 
HSPA2 GGTGGTCGTTAGTTGATTTC CGACGCACGAATAAATAATAC 133 
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IRX4 TGGGTAGTTGCGAGTTTTTC TACATAAATCGACGCTCCAA 190 
ISL2 AAAGTCGGACGTTATTGGAC AAAAACGCGATCGCTACTAC 215 
KDELR3 GTCGTCGGGTCGTTTAGTTC ACGACTACCACGTCTCCGA 228 
MACF1 GTGTAGATAAAGGCGCGGTC  ACGAAAAAAACCGACCGA  171 
NEFH AGGTTATGATGAGTTTCGGC  CACGAATAAAAACCGCTAAAA  155 
OSR1 AGTTCGGAAGTTCGGGTAGAC CTACCTTCGAAACGAAACCG 191 
OTX2 TCGATGTTTTTTTGCGAAC ACGTTTCGACGACGTTTTAC 183 
PBX3 TAGAGTTTAATGAGCGCGC CGCGAACCGAACTAAAAA 163 
POU4F2 AGATTGATAGTAGAGGCGGC ACTAATCCCGACTACCGAAA 156 
PRLHR GAAGCGAGATCGGATTATC TATTTACGATCCTCGCAATC 158 
REC8L1 AGTTTGACGTATTACGTGGC CGTTCGAATCTAAATCGAAA 229 
SHOX2 TAGTTAATATGGCGTGGGC CCGATATTATACCGCACAAA 160 
SLFN13 GCGTTAGTGAGAATTTGGTC CGACGACCGATACTCTATACTC 202 
SLFN13 CGCGGTGTTTGGTTAATTTC GAATCGAACGACACTCGATTC 247 
SMO GGGGAGTCGTGTATTTCGTTTCG CGCCCCCGCCTACTCCTCG 170 
STX16 TTTAGTTGTATAACGAACGCGC GTACGAAACCCCCAAACG 102 
TAL1 GGGGTGTGTGGTTTTTGC CCGACTTAATCAACCCCG 115 
THSD4 GGTTTCGTAGGAGTCGTAGC  CGACCCGTCTTAACCCTATA  222 
TMTC1 TGAAAAGTCGGGAATTTTTC  CCCACTTACGATATCCGACT  155 
ULBP1 TGGTTTTTTCGAATATCGC CTTCAACCGAACATATTCGA 154 
WFIKKN2 TGTGCGATTTTGGATAAGTC CGACGACTAAAACGAATCAC 229 
XRCC3 CGGAGTTTGAATTTCGTTTTATC CCTTCTCCTCCAATAAACG 187 
ZFYVE21 CGGTTCGTAGTTCGGTTCGGC CCAATCCGTATAAAAACACCG 232 
ZNF667 TACGTTTAGATGATCGGGAC TATTACGCCTACGTAACCGA 221 
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6.3.4 MSP analysis 
Materials:     
Master mix (for one reaction): ddH2O  13,2µl 
    dNTPs (BIOLINE; #39025) 3,2µl 
    PCR-Buffer (QIAGEN;#203205)       2,5µl 
    “Primer pair mix” specific 
for the gene of interest                   
 1,0µl 
 Hot start TAQ polymerase           (QIAGEN; #203205)    0,2µl 
    
Sodium bisulfite treated DNA, Agarose LE (Promega; #V-3125), Electrophorese buffer 
(sterile filtrated): 1x TAE (Tris/Acetic/EDTA Buffer; BIO-RAD; # 1610743), gel-red 
10000x (Biotium; #41003/41003-1); Bromphenol blue (Sigma-Aldrich; #B-5525), 
100bp DNA size marker (INVITROGEN; #15628-019), Loading buffer (0.05% 
bromphenol blue,  40% saccarose, 0.1M EDTA, 0.5% SDS and ddH2O to a final volume 
of 10ml; the buffer has to be sterile-filtrated) 
 
Ingredients for the MSP master mix (stored at -4°C) were defrosted and the PCR-tubes 
(200µl capacity) were marked. Then 20µl of master mix and 25ng DNA were transferred in a 
PCR-tube. After mixing the tubes were placed in the PCR cycler (GeneAmp PCR System 
9700). To analyze MSP results, an agarose gel-electrophoresis was performed. An agarose 
gel was prepared out of 180ml 1xTAE and 3.6g agarose (to obtain a 2% agarose gel). After 
boiling in the microwave the agarose was cooled with cold water, 3µl gel-red were added 
and the gel-tray was filled with the agarose gel. By cooling the gel to room temperature the 
gel ingredients polymerized. 2µl loading buffer were added to all PCR samples and 12µl from 
that mixture were loaded onto the gel. In addition, 3µl of a 100bp size marker were loaded 
onto the gel. The separation process took approximately 30 minutes at 170 volt. Due to the 
ability of gel-red to fluorescence under UV-light the results became visible.  
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6.4 Expression microarray analysis 
Isolated RNA was purified before the use of Affymetrix U133 plus 2.0 arrays.  
6.4.1 RNA clean-up with the MinElute Kit (Qiagen) 
Each step of this approach was performed according to the manufacturer’s instructions. 
100µg RNA were diluted in RNAse-free water to a total volume of 100µl, 350µl RLT Buffer 
were added and mixed by vortexing the sample. Afterwards 250µl EtOH (abs.) were added 
and mixed with a pipette. 700µl from this solution were transferred onto a “MinElute” 
column for a 22 minutes centrifugation step at 10000rpm. Afterwards the flow through was 
again transferred onto the membrane of the column for a second centrifugation step to 
increase the amount of bound RNA. Accordingly the column was transferred into a new 2ml 
collection tube, 500µl RPE buffer were added and the mixture was centrifuged again. The 
flow through could be discarded and 500µl EtOH (80%) were added to the column. After two 
minutes of centrifugation at 10000rpm the flow through was discarded and the column was 
placed in a new 2ml collection tube. To remove the remaining alcohol the column was 
centrifuged for five minutes at maximum speed. Again the column was transferred to a new 
1.5ml collection tube and 14µl RNAse free water were added onto the middle of the 
columns membrane. To elute RNA from the column a centrifugation step of one minute at 
maximum speed was performed. The obtained concentration was checked and had to be 
above 1µg/µl to be able to perform the following steps.  
6.4.2 Double strand cDNA synthesis 
10µg of the purified RNA were diluted in RNAse- free water to a final volume of 9µl in 
PCR tubes and 2µl T7 oligo dT primer were added. The sample was incubated at 70°C for ten 
minutes followed by a 2 minutes incubation step at 4°C and then transferred on ice. To 
collect the evaporated liquids a short centrifugation step is performed. Now 4µl 5x first-
strand reaction buffer, 2µl 0.1M DTT and 1µl 10mM dNTP mix were added and mixed 
thoroughly. After incubation the sample was put to 42°C for two minutes, 1.5µl SSII Super 
script reverse transcriptase were added and the sample was again incubated at 42°C for 60 
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minutes. The following steps had to be performed strictly on ice. 91µl DEPC-water, 30µl 5x 
second strand buffer, 3µl 10mM dNTP mix, 1µl E.coli DNA ligase, 4µl E.coli DNA polymerase I 
and 1µl E.coli RNAse H are added, mixed and the sample was incubated at 16°C for two 
hours. Now 2µl T4 DNA polymerase could be added and again incubated at 16°C for 5 
minutes. The sample was put on ice and 10µl 0.5M EDTA (pH=8.0) were added.  
6.4.3 Double strand cDNA clean-up  
2600µl of cDNA binding buffer were added to the ds cDNA from step 6.4.2 and vortexed 
for 3 minutes. Using a color based pH indicator (yellow at pH 5) the adequate pH was 
adjusted by adding the right amount of 3M NaAc. The mixture was transferred in 500µl steps 
into a cDNA “Cleanup” spin column and consequently centrifuged at 10000rpm for one 
minute. The obtained flow through was discarded. Then the column was transferred to a 
fresh 2ml collection tube, 750µl cDNA washing buffer were added, the column was 
centrifuged for one minute at 10000rpm and the flow through was discarded. The whole 
amount of washing buffer was eliminated from the column by centrifuging at full speed for 5 
minutes. Accordingly the column was transferred to a new collection tube. 14µl cDNA 
elution buffer were added onto the middle of the membrane and incubated for one minute. 
The cDNA was eluted from the column by a centrifugation step at full speed for one minute. 
Then the cDNA was stored at -80°C or was immediately used for the in vitro transcription 
process.  
6.4.4 In vitro transcription 
6µl of the purified ds cDNA were diluted in 16µl RNAse free water and 4µl 10x HY 
reaction buffer, 4µl 10x biotin labeled ribonucleotides, 4µl 10x DTT, 4µl RNAse inhibitor mix 
and 2µl T7 RNA polymerase were added to a final volume of 40µl. The ingredients were 
mixed thoroughly and were collected by spinning the tube. Then an incubation step of 16 
hours at 37°C was performed. The solution had to be mixed every 30 to 40 minutes. The 
sample was stored at -80°C or the following clean-up step was performed immediately.  
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6.4.5 cRNA clean-up  
The cRNA sample and 60µl DEPC water were vortexed together for three minutes, 
afterwards 350µl IVT cRNA binding buffer were added and vortexed again. After adding 
250µl EtOH the solution was mixed. Then, the mixture was transferred to a cleanup spin 
column and centrifuged for 24 minutes at 10000rpm. The column was transferred to a new 
collection tube, 500µl IVT cRNA wash buffer were added and the column was again 
centrifuged for 44 minutes at 10000rpm. Consequently, the flow through is discarded. 500µl 
EtOH (80%) were added to the column and the same centrifugation step as described before 
was performed. To eliminate the whole amount of EtOH the column was centrifuged at full 
speed for five minutes and then the column was placed into a new collection tube. For the 
elution step 11µl RNAse free water were added onto the middle of the membrane and the 
column was centrifuged at full speed for one minute. Additional 10µl of RNAse free water 
were added onto the columns membrane. After the last centrifugation step at full speed for 
one minute the concentration of cRNA had to be determined and cRNA was stored at -80°C 
or immediately fragmented.       
6.4.6 cRNA fragmentation  
15µg of cRNA were fragmented in one approach. The cRNA was diluted in DEPC-water to 
a final volume of 16µl. 4µl fragmentation buffer were added and the sample was placed in 
the thermo-cycler at 94°C for 34 minutes.  
During that time the microarray was prepared. (Important: the microarray had to be at 
room temperature 30 minutes prior to use, storage of the microarray at 4°C)   
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6.4.7  Microarray preparation and hybridization 
PreHyb-buffer is prepared (volumes needed for 6 chips): 
acetylated BSA  (50mg/ml) 15µl 
HS-DNA  (10mg/ml) 75µl 
2xMES-hyb.-buffer  750µl 
DEPC-water   660µl 
  
Then 230µl of the buffer were added to the microarray. After 15 minutes of incubation at 
40°C on a rotating platform in an incubator the microarray was washed with 1x MES-hyb.-
buffer, which had been previously made out of a 2x MES-hyb.buffer. 20µl of the fragmented 
cRNA were added to 230µl of hybridization buffer. The hybridization buffer contains: 
  
HS-DNA  (10mg/ml) 15µl 
acet. BSA  15µl  
20 x eukaryotic controls  (Bios.) 15µl  
Oligo B2  15µl 
2 x MES-hyb.-buffer  750µl  
DEPC-water  570µl  
   
This approach was vortexed, collected by a short centrifugation step and incubated at 
95°C for five minutes. Next it was centrifuged at full speed for five minutes. PreHyb-buffer 
was removed from the microarray and the cRNA-buffer mixture was added to the 
microarray. The hybridization was performed for 16 hours at 45°C on a rotating platform in 
an incubator.  
6.4.8 Washing and scanning of microarrays  
cRNA buffer mix was removed from the chip and transferred to a new 1.5ml tube. The 
microarray was washed immediately twice with 230µl 6xSSPE-T and the solution was left in 
the microarray. The microarray was put into the biopolis shared facilities (BSF) and it was 
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turned on for five minutes. The chip was washed twice with MES-wash buffer. The solution 
of the second washing step was left on the microarray and the chip was incubated for 30 
minutes at 45°C (rotating). The streptavidin staining solution was prepared, containing:   
 
Streptavidin, recombinant  (1mg/ml; in DEPC-water) 15µl 
acet. BSA  75µl  
2 x stain buffer  750µl  
DEPC-water  660µl  
   
 After 30 minutes incubation the MES-wash buffer was discarded and 230µl of the 
streptavidin staining solution were added. After a 15 minutes incubation step at 40°C on the 
rotating platform the solution was discarded and the microarray was washed twice with 6x 
SSPE-T. Afterwards the microarray was incubated for five minutes in the BSF with 6x SSPE-T. 
During this time the biotinylated anti-streptavidin solution was prepared containing:    
 
biotinylated anti-Streptavidin 6µl 
acet. BSA 60µl  
2 x stain buffer 750µl  
DEPC-water 684µl  
  
The microarray was washed once with MES-wash buffer and then 230µl biotinylated 
anti-streptavidin solution were added and incubated for 30 minutes at 40°C on a rotating 
platform. After that the buffer was discarded and the microarray was washed twice with 
SSPE-T. During five minutes incubation of the microarray in the BSF the streptavidin 
phycoerythrin (SAPE) solution was prepared, containing:  
 
Streptavidin R-Phycoerythrin  (4°C, without light!) 15µl  
acet. BSA  (50mg/ml)  75µl  
2 x stain buffer  750µl  
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DEPC-water   660µl  
   
 The SSPE-T solution is discarded from the microarray and the microarray was washed 
once with MES-wash. Next 230µl SAPE-solution were added to the chip. After 15 minutes 
incubation at 40°C on a rotating platform the chip was washed twice with 6x SSPE-T and 
again incubated for five minutes in the BFS. Then the chip was filled completely with 6x 
SSPE-T (to make sure that no air bubbles remain in the microarray). Half an hour before the 
scanning step the scanner and the computer were turned on. Next the microarray was 
scanned and analyzed.  
6.5 Methylated DNA immunoprecipitation (MeDIP)-chip analysis 
MeDIP-chip analyses were performed in the three adenocarcinoma cell lines A549, NCI-
H1993 and NCI-H2073 and in NHBE cells. Subsequent analyses were performed in 100 
primary lung tumor samples and in 100 corresponding non-malignant lung tissue samples. 
6.5.1 Fragmentation of genomic DNA 
Genomic DNA was fragmented using the ultrasonic device “Disrupter” (Diagenode, Liége, 
Belgium) to obtain DNA fragments of 200-800bp in length. During the 10 minutes process 
DNA was cooled with ice-water to prevent DNA denaturation. To confirm fragmentation an 
agarose gel was loaded with 300ng of sonicated DNA in 2 μl loading buffer.  
6.5.2 Methylated DNA immunoprecipitation (MeDIP) 
Materials: TE Buffer (for ingredients see 6.6)  
 5x IP buffer  
 Digestion buffer  
 Glycogen  (Roche Applied Science; #901393) 
 anti-5-methylcytosine antibody  (Eurogentec; #080917) 
 NaCl, 5M (Ambion; #AM9759) 
 Protein A agarose beads / 
Salmon sperm DNA 
(Millipore; #16-157) 
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3.2µg fragmented DNA was diluted in TE buffer to a final volume of 420µl. The DNA was 
heat-denaturated by incubation at 95°C for 10 minutes. Immediately the samples were put 
on ice for five minutes and evaporation was collected from the cap of the tube by a short 
centrifugation step in a pre-cooled centrifuge at 4°C. Next 20µl were removed from the 
sample for the input sample (referred to as input) and stored at -20°C. To the remaining 
400µl 100µl 5x IP buffer and 3.5µl anti-5-methylcytosine antibody were added. The sample 
was incubated on a rotating platform for two hours at 4°C. During this incubation period 
antibodies bound to methylated CpGs. 
80µl Protein A agarose beads (50% slurry) were pre-washed before incubation with the 
DNA-sample/antibody mixture. First the beads were centrifuged at 2000rpm for one minute 
and the supernatant was removed. Next 1ml 1x IP buffer was added to the beads mixed by 
resuspending and again centrifuged at 2000rpm for one minute. Again the supernatant was 
removed and the beads were resuspended in 40 µl 1x IP buffer. Pre-washed beads were 
added to the DNA/antibody sample followed by one hour incubation on a rotating platform 
at 4°C. During that incubation time the beads bound to the antibodies in the sample and a 
complex out of methylated DNA/antibody/beads was formed. Then the 
DNA/antibody/beads mixture was washed five times. Each washing step consisted of 
centrifugation at 2000rpm for one minute at 4°C, discarding the supernatant, adding 1ml of 
1x IP buffer and incubation for five minutes on a rotating platform at 4°C. Unbound DNA was 
removed away and only methylated DNA bounded to the antibody/beads complex 
remained. Next DNA had to be separated from the DNA/antibody/beads complex. A 
digestion buffer was prepared. In the last washing step the sample was centrifuged and the 
supernatant was discarded. 250µl digestion buffer and 7µl proteinase K mix (10mg/ml) were 
added after the last washing step. For separation of the proteins from DNA one hour 
incubation at 55°C was performed. Then DNA was extracted from the mixture using standard 
phenol/chloroform extraction and EtOH precipitation. 250 µl phenol were added and mixed 
by vortexing. The DNA containing aqueous phase was separated from the organic phase by 
centrifuging for 10 minutes at 14000rpm and 20°C. The upper aqueous phase was 
transferred into a new 1.5ml tube and 250µl chloroform/isoamyl alcohol were added. The 
sample was again mixed by vortexing and centrifuged at 14000rpm for 10 minutes. The 
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supernatant was transferred into a new 1.5ml tube and 1µl glycogen (20mg/ml), 20µl 5M 
NaCl and 500µl EtOH were added. After mixing the sample by hand it was put at -80°C for 20 
minutes. Next the sample was centrifuged in a pre-cooled centrifuge for 15 minutes at 4°C. A 
small pellet became visible. The supernatant was decanted and 500µl EtOH (70%) were 
added and the pellet was washed by vortexing the tube. Afterwards the sample was 
centrifuged for ten minutes at 14000rpm and 4°C. The supernatant was again decanted and 
a short centrifugation step ensured that the whole amount of alcohol was removed with a 
pipette. The pellet was dried on room temperature for 5 minutes and then dissolved in 20µl 
TE buffer (referred to as IP sample).  
The DNA concentration of the IP and the input samples was determined with a Nanodrop 
2000 (Thermo Scientific) yielding DNA amounts of 10-20ng/µl.         
6.5.3 Whole genome amplification (WGA) 
In general, ~5% of input DNA were recovered by MeDIP. However, for subsequent 
microarray analyses at least 4µg of immunoprecipitated DNA were required. Thus, DNA 
samples were amplified using WGA. A GenomePlex® Complete WGA Kit (WGA2) (Sigma-
Aldrich) was used and a double determination was performed to reach even higher DNA 
amounts. Each step of this approach was performed according to the manufacturer’s 
instructions. 
6.5.3.1 Step 1 of WGA 
A linker DNA-fragment was added to the sonicated DNA to allow amplification of 
different fragments with just one primer. We started with 20ng DNA per approach and 
ddH2O was added to obtain a final volume of 11µl. Master mix was added and the DNA was 
heat-denatured in the PCR cycler at 95 °C for 3 minutes. After denaturation it had to be 
worked strictly on ice. The ligase-enzyme was added and then a PCR program was started as 
followed:    
16 °C for 20 minutes 
24°C for 20 minutes 
37°C for 20 minutes 
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75°C for 5 minutes 
Maintain at 4°C 
6.5.3.2 Step 2 of WGA 
Now amplification of the linker/DNA-fragments combination was possible. The master 
mix and the enzyme were added to the sample from step 1. A PCR amplification program 
was started in the GeneAmp PCR System 9700 as following:  
 
Initial Denaturation  95°C for 3 minutes 
         Fourteen cycles each consisting of: 
Denaturation 94°C for 15 seconds 
Annealing/Extention 65°C for 5 minutes 
 
After finishing the program the sample was maintained at 4°C or store at -20°C until the 
following clean-up step was started. Each sample was amplified as duplicates.  
6.5.4 Clean-up of amplified DNA 
  The clean-up step was performed on a specific post PCR-working place. DNA was 
purified using a GenElute™ PCR clean-Up Kit (Sigma-Aldrich). The two approaches of each 
sample were pooled in one 1.5ml tube before starting the clean-up. Each step was 
performed according the manufactory’s manuals. The column had to be pre-washed. For 
that purpose 500µl column preparation buffer were put into the column and centrifuged at 
12000rpm for one minute. The PCR sample was combined with 5-fold volume of binding 
buffer and transferred into the column. Since DNA bound to the column DNA was separated 
from the buffer solution by centrifugation at 12000rpm for one minute. Bounded DNA was 
washed with 500µl washing buffer. A centrifugation step of two minutes at 12000rpm made 
sure that the whole amount of liquid was removed from the column. By adding 40µl elution 
buffer onto the middle of the membrane and after centrifugation the column for 1 minute at 
12000rpm DNA was eluted from the column. The amount of DNA was determined by using a 
Nanodrop 2000 (Thermo Scientific). DNA was stored in the elution buffer on -20°C.  
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6.5.5 Test for enrichment efficiency by quantitative real-time PCR 
We used the quantitative real-time PCR to ensure the enrichment of the methylated DNA 
in the IP sample compared to the input sample. The amount of a gene that is known to be 
methylated in somatic cells like H19, an imprinted gene, was measured in the IP and the 
input sample and the results were compared. In addition, the amount of another gene, 
namely GAPDH, a housekeeping gene, which is unmethylated in somatic cells was analyzed 
and the results obtained from the two samples were compared. H19 was highly enriched in 
the IP sample compared to the input sample and GAPDH was in higher amounts present in 
the Input sample. Enrichment of methylated sequences was calculated and normalized to 
GAPDH. An example for calculating the enrichment fold change is shown in Table 2. 
 
Table 2  
Calculation of the fold change in a qRT-PCR approach for A549.  
  GAPDH mean 
value 
H19 mean 
value 
Δ/ΔCt  DDCT  
(G) 
Expr 2 
exponential G 
A549 input 28,77 28,645 25,8 25,915 -2,73   1 
A549 input 28,52   26,03         
A549 IP 38,29 38,19 23,47 23,70 -14,49 11,76 3468,27 
A549 IP 38,08   23,92         
  
 
100ng of DNA were used for qRT-PCR analyses. H19 primers were designed in our 
laboratory. A TaqMan® Gene Expression Assays for GAPDH was designed by Applied 
Biosystems and were used as recommended from the manufacture. Reactions were 
performed in duplicates.   
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GAPDH:  TaqMan Master Mix  12,0µl 
  dd H2O 11,4µl 
  Primer   0,6µl 
 
H19:  SYBR Green Master Mix 12,5µl 
  dd H2O 10,5µl 
  Primer  1,0µl 
   
2µl of master mix were added to each reaction. 1µl (100ng/µl) of the DNA were added. 
Afterwards a stripe was put on top of the plate to close it thoroughly. A quantitative real-
time PCR was performed using the ABI 7000 cycler. 
6.5.6 MeDIP-chip analysis 
After confirming the enrichment of methylated DNA, the samples were sent to 
NimbleGen service laboratories for a second quality control step, sample labeling and 
hybridization to NimbleGen´s HG18 CpG plus Promoter arrays comprising 385.019 probes. 
These probes cover all reported Human Refseq gene promoters (24.659) and all reported 
CpG islands (28.226) annotated on the UCSC genome browser. IP DNA was labeled with 
Cyanine 5 (Cy5) and input DNA was labeled with Cyanine 3 (Cy3). Both Cy3 and Cy5 belong to 
the cyanine dye super family and both are reactive fluorescent dyes soluble in water. Cy3 
emits light with a wavelength of ~570nm, appearing green, Cy5 in contrast to that emits light 
with a wavelength of ~650/670nm which appear red.   
 IP and input samples were hybridized to the microarray chip. The promoter regions 
covered on the microarrays are 1kb and small CpG islands were extended at both ends for a 
total coverage of 700bp for more reliable detection. In addition, the arrays also contained 
DNA methylation positive control regions (H19/IGF2 cluster, KCNQ1 cluster, and IGF2R 
gene). Arrays were scanned on a GenePix 4200A Scanner using GenePix 6.0 Software and 
data were extracted from scanned images by using NimbleScan 2.3 (see Figure 13).  
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 For each cell line analyzed, we obtained scaled log ratio data for individual samples 
(control versus sample), log ratio GFF files and genome annotation GFF files.    
 
 
6.5.7 Statistical analysis of microarray data  
Data derived from MeDIP-chip were analyzed in cooperation with a team of 
biostatisticians from the Medical University of Vienna, Section of Medical Statistics, Vienna, 
Figure 13  
Schematic description of MeDIP-chip 
technology using NimbleGen microarray 
technique. First DNA is fragmented then 
methylated fragments are enriched in an IP 
sample. By comparing the IP sample to an 
input sample the methylated genes can be 
identified. Modified from NimbleGen® 
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Austria under the supervision of Prof. Dr. Martin Posch. In brief, data were analyzed using 
the bioconductor package Ringo. Data were normalized with NimbleGen-normalization 
(tukey’s biweight mean across each sample’s log2 ratios were computed and subtracted 
from the individual log2 ratios). For smoothing the data, a window size of 750bp was slid 
along the chromosome; the intensity at the genomic position x0 was replaced by the median 
over all intensities of reporters inside the window that was centered at x0. Quality 
assessment was done by histograms of the normalized and smoothed data and by 
correlation plots (raw data, normalized data and normalized + smoothed data).  
To test for potential differences in methylation between cases and controls two sample 
t-tests were calculated and p-values were corrected for multiple testing by the Benjamini-
Hochberg correction. Detailed results about the pattern of methylation between tumors and 
non-malignant lung samples and the frequencies of methylation of certain genes can be 
obtained with this method.  
Data derived from the gene expression microarray approach were analyzed as reported 
by Heller et al. (153) using Affymetrix Microarray Analysis Suite version 5 (MAS5) resulting in 
processed scanned chip images and a cell intensity file for each chip. Consequently, 
statistical analysis was performed using Bioconductor’s affy package. Using CyberT algorithm 
the significance of changes in the expression level of each gene was calculated. These tests 
were performed using the R-based Flexarray 1.3 software.  To set a gene as methylated 
changes in the expression level had to meet following criteria: gene expression levels 
obtained from drug treated cells had to be >2-fold higher than those obtained from 
untreated cells. Difference in gene expression between control and drug treated cells had to 
be statistically significant (P<0.01). 
Using the Parent-Child-Intersection algorithm of Ontologizer the obtained results were 
analyzed with Gene Ontology (GO) analysis (171). P-values of these analyses were calculated 
using one-sided Fisher exact test corrected for multiple testing using the Bonferroni method 
as provided in Ontologizer. 
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6.6 Buffer ingredients 
1xPBS:  NaCl  0.137M (Sigma-Aldrich; #. S7653) 
 KCl  2.7mM (Sigma-Aldrich; #P5405) 
 Na2HPO4 4.3mM (Sigma-Aldrich; # S9390) 
 KH2PO4 1.4mM  (Sigma-Aldrich; # P5655) 
 
Electrophorese buffer:  1 x TAE 
 
 (BIO-RAD; #1610743) 
Loading buffer: Bromphenol blue 0,05% (Sigma-Aldrich; #B-5525) 
 Saccharose 40%  
 EDTA (pH 8,0) 0,1M (Sigma-A.#43178-8) 
 SDS 0,5% (Sigma-Aldrich;#L-4522) 
 
PK-buffer: 
  
10ml 
 
 1,0M Tris (pH 8,0) 0.5ml (Biomol; #50005) 
 0,5M EDTA (pH 8,0) 20μl    (Sigma-Aldrich; #43178-8) 
 SDS 20% 50μl (Sigma-Aldrich; #L-4522)  
 Proteinase K10mg/ml 0.2ml (Roche Applied Science;#745723) 
 H2O 9.23ml  
TE Buffer Tris HCL pH 8.0 10mM (Biomol; #50005) 
 EDTA 1mM (Sigma-Aldrich; #43178-8) 
 
5x IP buffer 
  
10ml 
 
 100mM Na-Phosphat pH7 5ml (Fluka; #82637) 
 5M NaCl 1.4ml (Ambion; #AM9759)  
 10% Triton X-100 250μl (Sigma-Aldrich; #23472-9) 
 ddH2O  3.35ml  
 
Digestion buffer 
  
10ml 
 
 1M Tris HCl, pH 8.0 500μl (Sigma-Aldrich; #T3038-1L) 
 0.5M EDTA 200μl (Sigma-Aldrich; #E7889) 
 10%SDS 500μl (Sigma-Aldrich; #L-4522) 
 ddH2O 8.8ml  
 
Results   
 
54 Valerie Babinsky 0405551 
 
7 RESULTS 
The aim of our study was to better understand the role of DNA methylation in the 
pathology of NSCLC. To reach this goal we used different strategies: Firstly, we performed 
gene expression microarray analysis of three lung adenocarcinoma cell lines (A549, NCI-
H1993, NCI-H2073) before and after treatment with the epigenetically active drugs Aza-dC 
and/or TSA. Genes that showed no or low expression before and elevated expression after 
drug treatment could be identified as potentially epigenetically regulated. Secondly, we 
established a methylated DNA immunoprecipitation combined microarray (MeDIP-chip) 
approach and analyzed the genome-wide DNA methylation pattern of 3 adenocarcinoma cell 
lines (A549, NCI-H1993, NCI-H2073) and  NHBE cells. Based on the microarray results we 
selected several genes for further single gene methylation analysis of primary tumor and 
corresponding non-malignant lung tissue samples of 10 NSCLC patients using methylation-
specific PCR (MSP). 
7.1 Genome-wide DNA methylation analysis of NSCLC cell lines 
7.1.1 Gene expression analysis of the NSCLC cell lines A549, NCI-
H1993 and NCI-H2073 before and after treatment with Aza-dC 
and/or TSA   
Three NSCLC cell lines (A549, NCI-H1993 and NCI-H2073) were treated with the 
epigenetically active drugs Aza-dC, TSA or a combination of Aza-dC and TSA. Afterwards, 
expression microarray analyses were performed using Affymetrix HG-U133_plus_2.0 
GeneChips as reported recently (153). To identify potentially methylated genes microarray 
data from untreated and drug treated cells were compared. Genes found to be up-regulated 
after drug treatment had to meet the following criteria: the fold change in expression after 
drug treatment had to be >2-fold and differences in expression between untreated and drug 
treated cells had to be statistically significant (p<0.01). The universally methylated 
transketolase-like1 (TKTL1) gene was used as a positive control for loss of DNA methylation 
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and induction of gene expression as reported recently (154). TKTL1 was found to be up-
regulated by Aza-dC in all cell lines analyzed. Each experiment was performed in duplicate 
with independently grown cells to verify the comparability of microarray data as shown in 
Figure 14. 
 
Figure 14 
Scatter plots showing the comparability of expression microarray analyses. Comparison of microarray data of untreated 
cells (C1 vs. C2) are shown in (A) and of Aza-dC treated cells (A1 vs. A2) are shown in (B). Comparison of untreated and Aza-
dC treated cells is shown in (C). Light blue lines indicate the achieved fold change in gene expression. 
7.1.1.1 Aza-dC induced genes 
To determine the effect of DNMT inhibition on gene expression of NSCLC cell lines, we 
analyzed gene expression profiles of 3 NSCLC cell lines before and after treatment with Aza-
dC. As shown in Figure 15 up-regulation of gene expression as well as down-regulation of 
gene expression was observed. Since, we were interested in the identification of 
epigenetically inactivated genes we focused only on up-regulated genes.  
1059 probe sets (1.9% of 54.675 transcripts analyzed) were found to be up-regulated in 
the cell line A549, 286 probe sets (0.5%) in NCI-H1993 cells and 1296 probe sets (2.3%) in 
NCI-H2073 cells, respectively. Fold changes in expression varied from 2-fold to 201.6-fold, 
from 2-fold to 28.6-fold and from 2-fold to 83.15-fold in the cell lines A549, NCI-H1993 and 
NCI-H2073, respectively. As multiple probe sets for the same gene are present on Affymetrix 
microarrays, Aza-dC induced probe sets represent 768 unique genes in the case of A549, 219 
unique genes in the case of NCI-H1993 and 986 unique genes in the case of NCI-H2073. By 
comparing lists of up-regulated genes in the three cell lines we identified two genes 
commonly up-regulated in all three cell lines analyzed, 21 genes were up-regulated in both 
A549 and NCI-H1993, 6 genes were up-regulated in the cell lines NCI-H1993 and NCI-H2073 
Results   
 
56 Valerie Babinsky 0405551 
 
and 24 genes were commonly up-regulated in the cell lines A549 and NCI-H2073 (Figure 16). 
Overall, 1153 unique genes were found to be up-regulated in at least one of the three lung 
adenocarcinoma cell lines after exposure to Aza-dC.  
7.1.1.2 TSA induced genes 
Next, gene expression patterns of the three NSCLC cell lines were analyzed before and 
after treatment with TSA. Volcano plots of these results are shown in Figure 15. By gene 
expression microarray analyses of the three cell lines after TSA treatment we identified 1428 
up-regulated probe sets (2.6% of 54.675 transcripts analyzed) in the cell line A549, 2070 up-
regulated probe sets (3.8%) in the cell line NCI-H1993 and 453 up-regulated probe sets 
(0.8%)  in the cell line NCI-H2073, respectively. These probe sets represent 847, 1337 and 
287 unique genes in the cell lines A549, NCI-H1993 and NCI-H2073, respectively. Fold 
changes in expression varied from 2-fold to 63.37-fold, from 2-fold to 142.84-fold and from 
2-fold to 47.33-fold in the cell lines A549, NCI-H1993 and NCI-H2073, respectively. By 
comparing gene expression data after TSA treatment of the three cell lines we identified 19 
genes commonly up-regulated in all three cell lines analyzed, 92 genes were up-regulated in 
both A549 and NCI-H1993, 72 genes were commonly up-regulated in the cell lines NCI-
H1993 and NCI-H2073 and 21 genes were up-regulated in the cell lines A549 and NCI-H2073 
(Figure 16). Overall, 2254 unique genes were up-regulated in at least one of the three lung 
adenocarcinoma cell lines after exposure to TSA. By comparing microarray data from cells 
treated with Aza-dC and TSA we found that about 27% of identified genes after Aza-dC 
induction were additionally induced by TSA treatment (Figure 17).  
 
Results   
 
57 Valerie Babinsky 0405551 
 
 
Figure 15  
Volcano plots showing gene expression changes after treatment of NSCLC cell lines with Aza-dC, TSA or Aza-dC/TSA. Fold 
change and the statistical significance are plotted on the x- and y- axis, respectively.  Changes in the expression level of 
A549 are shown in a) after aa) Aza-dC, ab) TSA, and ac) Aza-dC and TSA treatment. Changes in the expression level in NCI-
H1993 in b) after ba) Aza-dC, bb) TSA, and bc) Aza-dC and TSA treatment and changes in the expression level in NCI-H2073 
are shown in c) after ca) Aza-dC, cb) TSA, and cc) Aza-dC and TSA treatment. Genes which were statistically significant 
(p>0.01) up-regulated >2-fold are shown in dark red. 
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Figure 16  
Venn diagrams summarizing the number of up-regulated genes in the cell lines A549, H1993 and H2073 after a) Aza-dC, b) 
TSA, and c) Aza-dC/TSA treatment. The region of overlap between all circles shows the number of genes up-regulated in all 
three cell lines analyzed. Regions of overlap between the circles of two cell lines indicate genes up-regulated in two of the 
three cell lines. Regions that do not overlap between circles indicate genes up-regulated in only one cell line. 
 
 
Figure 17  
Venn diagram showing genes which were up-regulated after Aza-dC treatment and genes that were up-regulated after TSA 
treatment. The overlap between the circles shows genes that were up-regulated by both Aza-dC treatment and TSA 
treatment.  
7.1.1.3 TSA and Aza-dC treated cells 
 Consequently, the lung adenocarcinoma cell lines A549, NCI-H1993 and NCI-H2073 
were treated with a combination of the two epigenetically active drugs Aza-dC and TSA. 
Volcano plots of the results are shown in Figure 15. Treatment of cells with the combination 
of Aza-dC and TSA resulted in up-regulation of 1769 probe sets (3.2%) in the cell line A549, 
of 2366 probe sets (4.3%) in NCI-H1993 and of 1462 probe sets (2.6%) in NCI-H2073, 
respectively. Fold changes in expression varied from 2-fold to 289.96-fold, from 2-fold to 
153.61-fold and from 2-fold to 139.11-fold in the cell lines A549, NCI-H1993 and NCI-H2073, 
respectively. In the cell lines A549, NCI-H1993 and NCI-H2073 these findings resulted in 
1186, 1452 and 1073 unique genes up-regulated after Aza-dC and TSA, respectively. 82 
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genes were commonly up-regulated in all three cell lines analyzed.  In addition, 128 genes 
were up-regulated in both A549 and NCI-H1993, 152 genes were commonly up-regulated in 
the cell lines NCI-H1993 and NCI-H2073 and in the cell lines A549 and NCI-H2073 166 genes 
were commonly up-regulated (Figure 16). 3088 unique genes were found to be induced in at 
least one of the three lung adenocarcinoma cell lines after exposure to the combination of 
Aza-dC and TSA.  
An interesting aspect is that 91% (1055 unique genes) of all genes up-regulated after 
Aza-dC (1153 unique genes) were additionally up-regulated after treatment with the Aza-
dC/TSA combination (see Figure 18 ). 
It has been reported that Aza-dC and TSA act synergistically in inducing expression of 
genes which are regulated by DNA methylation (172). By comparing microarray results from 
Aza-dC and Aza-dC/TSA treated cells we observed a synergistic up-regulation of gene 
expression in 37% of up regulated genes in A549, in 23% of up regulated genes in NCI-H1993 
and in 33% of up-regulated genes in the cell line NCI-H2073, respectively. Heat maps of 
these genes are shown in Figure 19. Examples for synergistically up-regulated genes, their 
chromosomal location, their physiological function and their relation to cancer are shown in 
Table 3. The genomic sequence of the 5’ regions of these genes was obtained from ESEMBLE 
database (release 58). Using the software “Methyl Primer Express v 1.0” 568 unique 
sequences were analyzed concerning their CpG-content. In total, 77% of the synergistically 
up-regulated genes were associated to a CpG-island within the 5’ region. These 438 genes 
were used for Gene Ontology (GO) analyses.  
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Figure 18 
Venn diagram showing genes which were up-regulated after Aza-dC treatment and genes that were up-regulated after Aza-
dC/TSA treatment. The overlap between the circles shows genes that were up-regulated by both Aza-dC treatment and the 
combinatorial treatment with Aza-dC/TSA.  
 
 
Figure 19 
Heat maps of genes which are synergistically up-regulated by Aza-dC and TSA in the cell lines (a A549, (b NCI-H1993 and (c 
NCI-H2073.  
a) b) c) 
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Table 3  
Examples of genes which were found to be synergistically up-regulated after drug treatment of A549, NCI-H1993 and NCI-H2073, their chromosomal location, 
their physiological function and knowledge about cancer association are described.  
 
Gene Cytoband Physiological function FC after treatment 
with Aza-dC 
FC after treatment 
with Aza-dC/TSA 
Down-regulation 
reported in 
CpG 
Island 
ALDH1A3 15q26.3 Cell detoxification 2,24 2,46 n/a 1 
DLX4 17q21.33 Transcription factor activity 3,21 4,52 Lung cancer 1 
TAL1 1p32 Transcription factor activity 5,55 7,11 n/a 1 
TMTC1 12p11.22 Membrane integration 7,43 14,30 n/a 1 
HEXIM1 17q21.31 Cyclin-dependent protein kinase 
inhibitor activity 
6,72 8,12 Breast cancer 1 
PTEN 10q23.3 EGFR downstream regulator 5,51 7,93 Colon, Prostate, 
Endometrial cancer 
1 
RECK 9p13.3 Endopeptidase inhibitor activity 4,44 6,74 Gastric, lung cancer 1 
NEFH 22q12.2 Cell death 27,36 106,64 Esophageal cancer 1 
NOX5 15q23 Cell proliferation regulation 2,25 3,40 n/a 1 
KSR1 17q11.1-q11.2 Member of the MAPK signaling 
pathway, cell proliferation 
2,03 8,12 Pancreas  cancer 0 
CPT1C 19q13.33 Lipid metabolic process 3,51 7,41 Skin cancer 1 
HIST1H2AE 6p22.2 Histone protein, DNA compactation 10,69 16,18 n/a 1 
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HOXA9 7p15.2 Transcription factor, development 
regulation 
2,39 6,35 Breast cancer 1 
IRX2 5p15.33 Regulation of transcription 7,53 8,74 Breast cancer 1 
 
FC, fold change; n/a, not available; information provided in this Table is depicted from references (131-136); (141); (143-144); (172) 
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7.1.1.4 Identification of cancer-associated genes 
Next, we performed Gene Ontology (GO) analyses to identify genes which are involved in 
cancer-related molecular pathways and thus may have tumor suppressor function within the 
synergistically up-regulated genes associated to a CpG island in their promoter region. The 
population set was defined as all genes which are represented on Affymetrix HG-
U133_plus_2.0 GeneChips. 438 genes were found to be synergistically up-regulated and 
were affiliated to a CpG island. These genes were analyzed using Ontologizer (171). Our 
analysis revealed up-regulation of already known targets for aberrant methylation such as 
PTEN (173). Even more interestingly we identified hitherto unknown target genes for 
methylation taking part in cancer-related pathways such as RECK (negative regulation of cell 
cycle), NOX5 (induction of apoptosis), CD274 (negative regulation of cell proliferation) or 
ATR (negative regulation of DNA replication). A summary of results from GO analysis is 
shown in Figure 20. 
 
 
Figure 20 
GO analyses showing the physiological function of synergistically up-regulated genes after Aza-dC and TSA treatment in 
three NSCLC cell lines A549, NCI-H1993 and NCI-H2073.  
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7.1.1.5 Single gene DNA methylation analysis of selected genes in tissue 
samples of NSCLC patients (n=10)  
Selected genes found to be synergistically up-regulated by Aza-dC and TSA were further 
analyzed by methylation-specific PCR in primary tumors and corresponding non-malignant 
lung tissue samples from 10 NSCLC patients. The genes were randomly selected and included 
TAL1, DLX4, TMTC1, NEFH, ALDH1A3, THSD4 and MACF1. Known targets for methylation in 
human tumors like ALDH1A3, as well as genes so far not further analyzed in cancer 
concerning DNA methylation like NEFH (microtubule cytoskeleton organization), TAL1 (cell 
proliferation), DLX4 (putative metastasis suppressor), THSD4 (proteolysis) and even genes 
like TMTC1 whose function is completely unknown, were part of the selection.  
As a first step MSP assays were designed for the 5´ regions of the seven genes using 
Methyl Primer Express® Software v1.0. Primer sequences and amplicon length are shown in 
6.3.3. As shown in Figure 21, methylation of the genes THSD4, TMTC1, NEFH, DLX4, 
ALDH1A3, and TAL1 were found more frequently in primary tumor samples than in 
corresponding non-malignant lung tissue samples. In contrast, the gene MACF1 was equally 
methylated in primary lung tumor samples and corresponding non-malignant lung tissue 
samples. Methylation was observed in primary NSCLC samples in different frequencies. The 
most frequently methylated genes were THSD4 and TMTC1 which were methylated in 90% 
and 80% of the analyzed tumor samples, respectively. Both genes were methylated in 0% of 
the analyzed non-malignant lung tissue samples. NEFH, DLX4, ALDH1A3 and TAL1 were 
methylated in 70%, 70%, 50% and 30% of the NSCLC samples and in 0%, 10%, 0% and 10% of 
the matching non-malignant lung tissue samples, respectively. Analyzing the methylation 
status of MACF1 revealed that methylation in the promoter region of this gene occurs not 
only in primary lung tumor samples analyzed but also in the corresponding non-malignant 
lung tissue samples.   
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Figure 21  
MSP analysis of methylation frequency of TAL1, DLX4, TMTC1, NEFH, ALDH1A3, THSD4 and MACF1 in primary lung tumor 
samples and corresponding non-malignant lung tissue samples of 10 NSCLC patients. Apart from MACF1 all genes were 
found to be tumor-specifically methylated; + positive control; - negative control; M 100bp ladder.  
 
7.1.2 Establishing MeDIP-chip 
Immunoprecipitation of methylated DNA sequences in combination with subsequent 
microarray analysis (MeDIP-chip) is a recently developed technique for determination of 
genome-wide DNA methylation. Using an anti-5-methylcytosine antibody, methylated DNA 
fragments are enriched and subsequently hybridized to microarrays. A detailed description 
of the MeDIP approach is provided in section 6.5.2. 
To optimize immunoprecipitation different setups were analyzed and evaluated. The 
approach was optimized for the following variables: duration of the sonication step, duration 
of the incubation step with the antibody as well as with the Protein A agarose beads and the 
number of washing steps. For testifying the enrichment of methylated DNA fragments and 
the exclusion of unmethylated fragments qRT-PCR for the imprinted gene H19 (methylated 
control) and the housekeeping gene GAPDH (unmethylated control) was performed as 
described in 6.5.5. Since, the obtained amount of DNA after MeDIP is very low (10-20ng/µl) 
amplification of the IP samples was performed using a whole genome amplification 
approach (see section 6.5.3 for exact WGA process). According to suggestions from 
NimbleGen concerning fold enrichment of methylated DNA fragments we chose a fold 
change >500 as cut-off for efficient MeDIP assay. 
Fragmentation of genomic DNA is the fundament for separating methylated DNA from 
unmethylated DNA. Thus, we aimed to obtain DNA fragments of 200-800 bp in length. 
ALDH1A3 
DLX4 
TAL1 
NEFH 
TMTC1 
THSD4 157 bp 
 
201 bp 
150 bp 
182 bp  
115 bp 
152 bp 
MACF1 103 bp 
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Minimal variation in the time of sonication revealed changes in the fragmentation state of 
the genomic DNA. Sonication for 5 minutes resulted in fragments of up to 2000bp in length. 
After sonicating genomic DNA for 10 minutes mainly fragments were present with a length 
between 150bp and 800bp in length. Sonicating genomic DNA for 15 minutes resulted in 
fragments which were 100-600bp. The difference between sonication for 5 minutes and 
sonication for 10 minutes was drastically. We chose 10 minutes sonication time with 
intervals of 30 seconds sonication followed by 30 seconds break as optimal setup because 
DNA fragments are long enough for the needed whole genome amplification step but not 
too long to ensure separating the methylated fragments from the unmethylated ones (see 
Figure 22). 
 
Figure 22  
Agarose gel-electrophones image showing a) genomic DNA which was not sonicated, b) genomic DNA sonicated for 5 
minutes, c) genomic DNA sonicated for 10 minutes and d) genomic DNA sonicated for 15 minutes. M, 100bp ladder. 
 
For enrichment of methylated DNA fragments 3.2µg sonicated DNA were incubated with 
3.5µg of an antibody specific for 5-methylcytosine for two hours at 4°C. Incubation time with 
the antibody as well as the consequent incubation with protein A agarose beads is sufficient 
for specific antibody binding to methylated fragments. However, if applied in the wrong way 
it can also lead to unspecific binding. At first, the incubation period with the antibody was 
optimized. One, two and three hours of incubation were tested. Incubation of genomic DNA 
fragments for one hour led to enrichment of low DNA amounts (<5ng/µl). However, for 
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subsequent experiments at least 10ng/µl DNA are required. Three hours of incubation 
yielded a high amount of DNA and unspecific antibody binding as determined by qRT-PCR. As 
shown in Figure 23 target sequences for primers specific for H19, which represents the 
methylated fragments, were present in equal amounts in the input sample and in the IP 
sample. Unmethylated fragments, which are depictured by amplification of GAPDH, were 
slightly enriched in the input sample compared to the IP sample. This amount of enrichment 
is not ensuring elimination of unmethylated fragments. The calculated fold change for 
enrichment of methylated DNA fragments in this approach was 34.78-fold.  
 
Figure 23 
qRT-PCR for H19 and GAPDH to test for enrichment of methylated DNA fragments after immunoprecipitation. Results of 
qRT-PCR analysis of the cell line A549 after incubation with the primary antibody for 3 hours are shown. Signals for H19 and 
GAPDH in the IP sample were compared to signals of the input sample. Methylated and unmethylated fragments of the 
genomic DNA are present in both the IP and the input sample. 
 
Incubation for two hours yielded sufficient DNA for further experiments and kept the 
specificity of the antibody on a high level.  
Equal experiments were conducted for the incubation period of DNA-antibody 
complexes with protein A agarose beads. 3 different durations of incubation were tested: 
half an hour, one hour and two hours. After incubating only half an hour the DNA amount 
was too low for subsequent experiments (<5ng/µl). Setting the incubation time to two 
hours, we obtained unspecific interaction of protein A agarose beads with unbound DNA 
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fragments, leading to inefficient exclusion of unmethylated DNA fragments as shown in 
Figure 24. Methylated as well as unmethylated fragments are present in similar amounts in 
both the input and the IP sample. Amplification of H19 is becoming detectable around cycle 
number 19 in the IP sample and only one cycle later in the input sample. This approach is not 
sufficient to enable the exclusion of unmethylated fragments from the IP sample and to 
enrich methylated ones in the IP sample. The fold change of enrichment was in this case only 
38.45-fold.  
 
Figure 24 
qRT-PCR for H19 and GAPDH to test for enrichment of methylated DNA fragments after immunoprecipitation. Results of 
qRT-PCR analysis of the cell line A549 after incubation with protein A agarose beads for 2 hours are shown. Signals for H19 
and GAPDH in the IP sample were compared to signals of the input sample. Two hours of incubation allows unspecific 
interaction of the DNA fragment/antibody complex with the protein A agarose beads.  
 
Incubation with protein A agarose beads was optimally set to one hour because of 
minimal unspecific binding events and sufficient DNA yield for subsequent experiments. 
During the consequent washing steps unbound DNA is eliminated from the IP sample. 
Insufficient washing of DNA/antibody/agarose complexes leads to remaining of unbound 
DNA within the sample. This situation was observed after washing only 3 times. Exclusion 
from the unbound DNA was achieved after 5 washing steps. Thus, 5 washing steps were set 
as optimal parameter. 
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In summary, optimal parameters for efficient enrichment of methylated DNA fragments 
by MeDIP are as follows: sonication of genomic DNA for 10 minutes, followed by incubation 
with 3.5 µg primary antibody for two hours and a consequently incubation for one hour with 
protein A agarose beads. Unmethylated fragments are eliminated with 5 washing steps. The 
graph of the qRT-PCR result for the cell line A549 is depictured in Figure 25. In this case 
enrichment of methylated fragments was archived in the IP sample in comparison to the 
input sample. Unmethylated fragments are present in the input sample but not in the IP 
sample. Amplification of GAPDH in the IP sample is only starting after the 40th cycle, and can 
be seen as unspecific amplification. The fold change of enrichment for this sample amounted 
to 4069-fold. 
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Table 4  
Summary of the optimization process of MeDIP approach. Duration and intensity of DNA sonication, duration of the incubation steps, number washing steps 
were optimized. 
 
DNA sonication 5 minutes  Most DNA fragments are too long (up to 2000bp). 
Methylated and unmethylated regions can lie on 
one fragment 
 10 minutes  Optimal length of DNA fragments (200bp - 800bp) 
 15 minutes DNA fragments are too small. Thus, consequent 
amplification is inefficient (100bp – 600bp) 
Incubation time with primary antibody (AB) 1 hour Time is too short for optimal DNA binding resulting 
in very low amounts of recovered DNA (<5ng/µl). 
 2 hours Optimal incubation period. Efficient enrichment of 
methylated DNA with a low amount of unspecific 
binding.    
 3 hours Efficient enrichment of methylated DNA with a 
high amount of unspecific binding.  (see Figure 23)  
Incubation time with Protein A beads  30 minutes Subsequent qRT-PCR reveal that the amount of 
methylated DNA is significantly reduced (<5ng/µl). 
 1 hour Subsequent qRT-PCR show adequate amount of 
methylated DNA, unmethylated DNA is mostly 
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excluded 
 2 hours Subsequent qRT-PCR displays that longer 
incubation increases the number of unspecific 
bonds (see Figure 24) 
Number of washing steps 10 Unbound DNA is eliminated, very time consuming, 
minimal amounts of methylated DNA are lost in 
every further step 
 5 Unbound DNA is eliminated; only minimal  loss of 
methylated DNA  
 3 Subsequent qRT-PCR reveals significant amount of 
unmethylated DNA, washing was insufficient 
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Figure 25  
The graph depicturing the result of the qRT-PCR analysis of the cell line A549 after MeDIP under optimal conditions. The IP 
sample was compared to the Input sample. Primers specific for H19 and primers specific for GAPDH were used for this 
approach. Enrichment of methylated regions is confirmed shown by H19. Unmethylated regions shown by GADH are only 
produced unspecific. 
 
7.1.2.1 MeDIP-chip analysis 
After successful establishing the MeDIP assay the lung adenocarcinoma cell lines A549, 
NCI-H1993 and NCI-H2073 and Normal Human Bronchial Epithelial Cells (NHBEC) were 
consequently analyzed by MeDIP-chip. Labeling and microarray hybridization were 
performed by “NimbleGen” using “HG18 CpG plus Promoter” arrays comprising 385.019 
probe sets. These probes cover all reported Human Refseq gene promoters (24.659) and all 
reported CpG islands (28.226) annotated on the UCSC genome browser. Arrays were 
scanned on a GenePix 4200A Scanner using GenePix 6.0 Software and data were extracted 
from scanned images by using NimbleScan 2.3 extraction software (NimbleGen Systems, 
Inc.). Raw data (.pair) files were used for detailed statistical analysis as described below. In 
addition, processed data files for each cell line analyzed were generated and provided by 
NimbleGen using default setting from NimbleScan 2.3 software.  
To verify the MeDIP-chip results NimbleGen includes genes into the analyses with known 
methylation status. Since, methylation of H19 is known to occur in all somatic cells this gene 
was used as our positive control. The house keeping gene GAPDH, which is unmethylated in 
all somatic cells was used as negative control. All cell lines revealed methylation of the H19 
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promoter region. The promoter region of GAPDH was unmethylated in all cell lines analyzed 
(see Figure 26).  
 
 
Figure 26 
Quality control step: NimbleGen includes genes with known methylation status into the microarray analyses to confirm the 
obtained data. Example genes are GAPDH and H19. GAPDH which is a house keeping gene and in this position never 
methylated in somatic cells was unmethylated all cell lines analyzed. H19 which is a development gene and in this function 
methylated and silenced in all somatic cells was methylated in all cell lines analyzed.  
 
Statistic analysis of MeDIP-chip data was performed in cooperation with biostatisticians 
from the Medical University of Vienna, Section of Medical Statistics, Vienna, Austria under 
the supervision of Prof. Dr. Martin Posch. Differentially methylated regions between lung 
cancer cell lines and NHBECs were determined as described in 6.5.7. Due to statistic 
deviation the cell line NCI-H2073 had to be excluded from further analysis.  
This statistical analysis revealed that 31.786 probes were differentially methylated 
between lung cancer cell lines and NHBECs with a p-value <0.05. After correction for 
multiple testing (Benjamini-Hochberg) 375 probes remained with a p-value <0.05. These 
probes were annotated and dereplicated yielding 47 unique tumor-specifically methylated 
protein encoding genes. Detailed information about these genes is shown in Table 5. 
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Table 5 
47 tumor-specifically methylated genes identified by MeDIP-chip analysis in NSCLC cell lines  
Accessiona Gene name Gene symbol Cytoband 
 
AK098187 Chromosome 14 open reading frame 39 C14orf39 14q23.1 
AAH15763 Epidermal growth factor receptor pathway substrate 8-like protein 1-like EPS8L1 19q13.42 
NP_001073927 Homeo box even-skipped homolog protein 2 EVX2 2q31.1 
Q6ZQR6 n/a FLJ45983 10p14 
U13223 Forkhead box D4 FOXD4 9p11-q11 
AF452723 Forkhead box D4 like 1 FOXD4L1 2q14.1 
AL031777 Histone 1, H2ae HIST1H2AE* 6p22.2-p21.1 
AF531289 Histone 1, H2bf HIST1H2BF 6p21.3 
NM_005519.1 Homeo box (H6 family) 2 HMX2* 10q25.2-q26.3 
AI581335 Homeo box A2 HOXA2* 7p15-p14 
AK056567 Homeo box A3 HOXA3 7p15-p14 
AI277552 Homeo box A4 HOXA4 7p15-p14 
AF010258 Homeo box A9 HOXA9* 7p15-p14 
AF016029 Homeo box B3 HOXB3 17q21.3 
AF069333 Insulin-like growth factor 2 receptor IGF2R 6q26 
AF319967 Iroquois Homeobox protein 2 IRX2* 5p15.33 
BC020470 LIM Homeobox 1 LHX1 17q12 
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AJ277915 LIM Homeobox 9 LHX9* 1q31-q32 
XR_041919.2 Phosphodiesterase 4D interacting protein-like LOC199882 1q21.2 
AK057663 Hypothetical protein LOC285074 LOC285074 2p11.1 
XM_370758.3 Hypothetical gene supported by BX248251 LOC387978 14q12 
XM_931960 Hypothetical protein LOC643982 LOC643982 17q25.3 
XM_928920.1 Homo sapiens similar to forkhead box D4 like 3, transcript variant 1 LOC653427 9q21.11 
BX537794 Nuclear factor I/X (CCAAT-binding transcription factor) NFIX 19p13.3 
AB007948 Nicotinamide nucleotide adenylyltransferase 2 NMNAT2* 1q25 
NM_145260.2 Odd-skipped related 1 OSR1 2p24.1 
AB037505 Orthodenticle homolog 2 (Drosophila) OTX2 14q21-q22 
AK074881 Paired box gene 6 (aniridia, keratitis) PAX6 11p13 
AF152305 Protocadherin alpha 1 PCDHA1* 5q31 
AF152306 Protocadherin alpha 10 PCDHA10* 5q31 
AF152307 Protocadherin alpha 11 PCDHA11* 5q31 
AF152308 Protocadherin alpha 12 PCDHA12* 5q31 
AF152309 Protocadherin alpha 13 PCDHA13* 5q31 
AF152310 Protocadherin alpha 2 PCDHA2* 5q31 
AF152311 Protocadherin alpha 3 PCDHA3* 5q31 
AF152312 Protocadherin alpha 4 PCDHA4* 5q31 
AF152313 Protocadherin alpha 5 PCDHA5* 5q31 
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AF152314 Protocadherin alpha 6 PCDHA6* 5q31 
AF152315 Protocadherin alpha 7 PCDHA7* 5q31 
AF152316 Protocadherin alpha 8 PCDHA8* 5q31 
AC005609 Protocadherin alpha 9 PCDHA9* 5q31 
AB015671 Paired-like Homeobox 2b PHOX2B 4p12 
AF048720 Paired-like Homeo domain transcription factor 2 PITX2 4q25-q27 
NM_004575 POU domain, class 4, transcription factor 2 POU4F2 4q31.2 
AF022654 Short stature Homeobox 2 SHOX2* 3q25-q26.1 
AAH36458 Solute carrier family 32 (GABA vesicular transporter), member 1 SLC32A1 20q11.23 
NM_152476 Zinc finger protein 560 ZNF560 19p13.2 
 
a GenBank accession number 
* Asterisks indicate genes which are identified by MeDIP-chip and whose expression was up-regulated after Aza-dC or Aza-dC/TSA treatment 
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7.1.2.2 Functional analysis of tumor-specifically methylated genes 
We used Ontologizer (171) to functionally categorize the 47 tumor-specifically 
methylated genes. As shown in Figure 27 two major groups of tumor-specifically methylated 
genes were identified: transcription factors (represented as GO:0030528, transcription 
regulator activity) and cell adhesion molecules (represented as GO:0005509, calcium ion 
binding). Detailed results of GO analysis are shown in Table 6. 
 
 
Figure 27 
Enrichment of GO terms by means of molecular function. Enriched nodes are colored in different intensities of yellow 
depending on adjusted p-values (more significant enrichment corresponds to more intense yellow). First ratio corresponds 
to the proportion of GO terms in the human genome and the second ratio corresponds to the proportion of GO terms in the 
study group. 
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Table 6 
Functional characterization of 47 tumor-specifically methylated genes according to GO categories 
GO ID Biological process Study Count Population Count Adjusted p-value 
GO:0032502  Developmental process 26 3529 2.56E-10 
GO:0032501  Multicellular organismal process 26 3926 1.63E-09 
GO:0022610  Biological adhesion 13 879 1.30E-07 
GO:0009058  Biosynthetic process 20 5866 2.65E-05 
GO:0006139  Nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
20 5056 
2.65E-05 
GO:0016337  Cell-cell adhesion 13 343 0.00018279 
GO:0008150  Biological_process 37 21165 0.0004549 
GO:0007156  Homophilic cell adhesion 13 167 0.00191185 
GO:0007224  Smoothened signaling pathway 2 22 0.00225362 
GO:0010467  Gene expression 19 5014 0.0167489 
GO:0048856  Anatomical structure development 24 2232 0.0167489 
GO:0046530  Photoreceptor cell differentiation 2 11 0.0299079 
GO:0034960  Cellular biopolymer metabolic process 19 5594 0.0299079 
GO:0007399  Nervous system development 17 837 0.0380023 
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GO ID Molecular function 18 1867 2.67E-09 
GO:0043565  Sequence-specific DNA binding 17 749 2.14E-07 
GO:0005509  Calcium ion binding 13 1270 0.00018279 
GO:0003676  Nucleic acid binding 20 5142 0.00453889 
GO:0003677  DNA binding 19 3101 0.0129824 
GO ID Molecular function 14 3812 0.00161287 
GO:0005575  Cellular_component 37 22009 0.00161287 
GO:0005634  Nucleus 21 6172 0.0299079 
The study count is the total number of genes with the corresponding GO annotation which were detected as tumor-specifically methylated in NSCLC cell lines 
The total count is the total number of genes present on the NimbleGen´s HG18 CpG plus Promoter microarray which have the corresponding GO annotation. 
The adjusted p-value is the calculated p-value for the enrichment analysis adjusted for multiple comparisons using the Bonferroni method. 
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We showed that tumor-specific methylation of transcription factors is present in lung 
cancer cell lines. 19 of the 47 genes identified to be methylated in lung cancer cell lines could 
be affiliated to the molecular function of transcription factors. One important super family of 
transcription factors is the homeo box family. DNA methylation within the promoter region 
of 4 genes out of 11 genes within the gene cluster HOXA was identified. HOXA2, HOXA3, 
HOXA4 and HOXA9 are methylated in their promoter region in the NSCLC cell lines A594 and 
NCI-H1993 but show only low methylation signal in the NHBE cells analyzed (see Figure 28). 
Additional genes like IRX2, LHX1, LHX9 and OTX2 were affiliated to the super family of 
transcription factors. Since in most cases one transcription factor regulates several other 
genes, these 19 genes enlarge the scope of these findings tremendously. 
28 genes were shown to be important for different development processes like cell 
proliferation or cell death. Both pathways are known to be de-regulated to a certain extend 
in cancer. HMX2, HOXA3, LHX1, LHX9 and PHOX2B were shown to be methylated in the 
NSCLC cell lines but not in the NHBE cells and all of them are important for the regulation of 
cell proliferation. Genes like IGF2R, OSR1 which are taking part in the regulation of the cell 
death were also among the genes identified as tumor-specifically methylated.  
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Figure 28 
Result sheet obtained from NimbleGen; the region of the HOXA gene cluster on chromosome 7 is shown. Results for the 
NSCLC cell lines A549 and NCI-H1993 are compared to the results for NHBE cells. Strong methylation signal in the promoter 
region of the genes HOXA2, HOXA3, HOXA4 and HOXA9 is shown in the NSCLC cell lines. 
 
Genes like PCDHA1 and PCDHA9 which are important for cell adhesion were identified as 
tumor-specifically methylated. Protocadherin genes are encoded in clusters. All 13 PCDHA 
genes are encoded in the cluster PCDH alpha. Our results reveal that all members of the 
PCDHA cluster (PCDHA1, PCDHA2, PCDHA3, PCDHA4, PCDHA5, PCDHA6, PCDHA7, PCDHA8, 
PCDHA9, PCDHA10, PCDHA11, PCDHA12 and PCDHA13) are tumor-specifically methylated 
(see Figure 29). 
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Figure 29 
Result sheet obtained from NimbleGen; the region of the PCDHA gene cluster on chromosome 5 is shown. Results for the 
NSCLC cell lines A549 and NCI-H1993 are compared to the results for NHBE cells. Strong methylation signal in the promoter 
region of every gene is shown in the NSCLC cell lines. 
 
7.1.2.3 Comparison of gene expression microarray results and MeDIP-
chip results of the cell lines A549, NCI-H1993 and NCI-H2073 
Comparing results obtained from MeDIP-chip analysis and the genes identified as 
statistically significant up-regulated after Aza-dC and/or TSA induction in at least one of the 
three lung adenocarcinoma cell lines, 21 genes were commonly identified. This shows that 
45% of the genes identified as methylated by the MeDIP-Chip method could be verified after 
induction with the epigenetically active drugs Aza-dC and/or TSA. Among these genes known 
target genes for methylation in caner like HOXA9 and IRX2 were found to be methylated by 
both techniques (174). OTX2 which is a transcriptional regulator has been identified as 
important for cell cycle regulation and induction of senescence (175).  
Tumor-specific methylation of 8 randomly selected genes was confirmed by MSP in 
primary lung tumor samples and corresponding non-malignant lung tissue samples of 10 
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NSCLC patients. As example OTX2 was methylated in 80% of the analyzed tumors. In 
contrast, none of the non-malignant tumor samples showed methylation of the OTX2 
promoter region. Also methylation of the promoter region of HOXA9 was identified to be 
tumor-specifically distributed. 90% of the tumor samples analyzed revealed methylation of 
the HOXA9 promoter region in comparison to methylation of 10% of the promoter region in 
non-malignant lung tissue samples. MSP results obtained by analyzing 10 primary NSCLCs 
and matching non-malignant lung tissue samples for methylation of OTX2 and HOXA9 are 
shown in Figure 30. MSP results for additional genes are shown in Figure 21. 
 
Figure 30  
MSP analyses of methylation frequency of OTX2 and HOXA9 in primary lung tumor samples and corresponding non-
malignant lung tissue samples of 10 NSCLC patients. All genes show a high degree of methylation in the tumor samples but 
only no or rare methylation signals in the corresponding normal tissue; + positive control; - negative control; M 100bp 
ladder 
 
OTX2 
HOXA9 
183 bp 
223 bp  
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8 DISCUSSION 
Changes in the epigenetic code, especially in DNA methylation patterns, are frequently 
occurring events in the pathogenesis of malignant diseases. To date about 100-150 genes 
are known to be aberrantly methylated in NSCLC. Most of this knowledge was gathered with 
time consuming DNA methylation analysis on single gene level. However, Costello et al. (4) 
reported previously that approximately 600 CpG islands are methylated in tumor cells. Thus, 
identification of novel target genes for methylation is of tremendous importance for the 
understanding of the molecular mechanisms leading to NSCLC. With the development of the 
microarray technique several years ago it became possible to analyze gene expression 
patterns in a genome-wide manner. Because DNA methylation, which is a reversible process, 
significantly contributes to the silencing of gene expression a combination of a 
pharmacological DNA demethylation assay combined with gene expression microarrays is a 
useful strategy to identify so far unknown methylated genes (12-14). Since this is a method 
which indirectly identifies methylated genes false positive results have to be expected. We 
used this approach on three NSCLC cell lines to better understand the impact of changes in 
the DNA methylation pattern on the pathogenesis of NSCLC. A major disadvantage of this 
technique is that it is only applicable to cells in cell culture but not to tissue samples. Cell 
lines are an optimal tool to get a first insight into a subject since cell lines are easy to 
cultivate, are highly available and depicture many features of in vivo cells.  However, cells in 
cell culture can accumulate aberrations in gene expression, morphology, metabolism and 
DNA methylation (124, 176, 177). This suggests that research results obtained only from cell 
lines may not accurately reflect the situation in a cancer cell in vivo.  
In recent years a novel genome-wide approach for methylation analysis called MeDIP-
chip was developed. MeDIP-chip has the advantage to be applicable to tissue samples 
making a direct comparison of DNA methylation pattern of primary tumors and 
corresponding non-malignant tissue samples possible. 
The aim of this project was to get more insight into the changes of DNA methylation 
patterns during pathogenesis of NSCLCs. To archive this aim we performed two different 
types of whole genome DNA methylation analyses. Additionally, selected genes were further 
Discussion   
 
85 Valerie Babinsky 0405551 
 
analyzed with the gene specific method MSP. In this way an optimal verification of the 
results obtained was ensured. 
At first we analyzed the gene expression profile of three NSCLC cell lines before and after 
treatment with the epigenetically active drugs Aza-dC and/or TSA and compared them to 
each other. A similar approach was already applied to NSCLC cell lines by Shames et al. (154). 
They identified 132 tumor-specifically methylated genes by analyzing expression of ~47.000 
transcripts after treatment of 7 NSCLC cell lines with the demethylating drug 5-aza-2´-
deoxycytidine (Aza-dC) and by comparing these results with data of 3 normal human 
bronchial epithelial cells (NHBEC). Additionally, Zhong et al. (178) identified 214 genes whose 
expression was up-regulated after drug treatment by using a similar approach and treating 9 
NSCLC cell lines with Aza-dC and TSA. Our results identified a large number of genes to be 
up-regulated after drug treatment.  
Many of the up-regulated genes were found to be involved in cancer-related molecular 
pathways such as cell cycle, cell adhesion and apoptosis. Thus far, epigenetic silencing was 
unknown for most of these genes. However, we also identified genes whose epigenetic 
silencing in lung cancer has already been reported including APC, p16, RASSF4, RASSF5, 
TIMP2 and HIC1 (179, 180). Seven genes which were synergistically up-regulated after Aza-
dC and TSA induction were selected for further MSP analyses of primary lung tumor samples 
and corresponding non-malignant lung tissue samples of 10 NSCLC patients. These analyses 
revealed tumor-specific methylation of six out of seven genes analyzed. The most frequently 
methylated genes in the primary NSCLCs were THSD4 and TMTC1.  
The function of TMTC1 is nearly unknown. Due to the identification of tumor-specific 
methylation of TMTC1 our data indicate that this gene is involved in the pathogenesis of 
NSCLCs. However, additional functional studies are necessary to characterize the association 
between TMTC1 and cancer development.   
Additionally genes like ALDH1A and NEFH were identified to be tumor-specifically 
methylated. ALDH1A3 has previously been shown to be a target for methylation in different 
types of cancer including gastric and breast cancer. As reported previously changes in 
expression of this gene can be set into relation to progression of liver, gastric or breast 
carcinomas (181). Our results indicate that this observation may also be true for NSCLC. 
Interestingly, methylation of NEFH has recently been correlated with duration of tobacco 
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smoking and esophageal squamous cell carcinomas (ESCC) (182). Further studies are needed 
to determine if NEFH methylation already occurs in pre cancerous lesions of the lung. If 
NEFH can be found to be methylated in these tissues, this gene might be potentially helpful 
for early diagnosis of NSCLCs.   
Recent studies revealed that DLX4 has metastatic inhibiting function (183). DLX4 was 
frequently methylated in primary lung tumor samples but was methylated only in 10% of the 
corresponding non-malignant lung tissue samples analyzed. Epigenetic inactivation of this 
gene might favor the metastatic potential of lung cancer cells. 
Besides tumor-specific methylation of certain genes we also observed that drug 
treatment of cells up-regulate genes whose methylation is not tumor-specific. As seen in 
Figure 21 methylation of the gene MACF1 was not only found in primary tumor samples but 
also in non-malignant lung tissue samples. Additional studies are necessary, to investigate 
MACF1 methylation. 
By comparing expression microarray results obtained from Aza-dC treated cells with 
results obtained from TSA treated cells, synergistically up-regulated genes were identified. A 
synergy in induction of gene expression of these two drugs was already observed (151). 
Several of the synergistically up-regulated genes are involved in cancer related pathways. 
One of them is HEXIM1 which shows transcription factor activity, and negatively regulates 
the cell cycle as well as the expression of vascular endothelial growth factor in an estrogen 
dependent manner (184). Recently, HEXIM1 de-regulation in ovarian cancer was identified 
but the mechanism of de-regulation for this gene is unknown so far (185).  
Identifying NOX5 to be synergistically up-regulated after Aza-dC and TSA is standing in 
controversy with findings from Hong et al. (186). They identified NOX5 to induce 
pathogenesis of esophageal adenocarcinoma by mediating production of reactive oxygen 
species and cell proliferation (186).  
ATM which has been shown to possess a key role in regulation of DNA replication in 
stress related situations was tumor-specifically methylated in the cell lines analyzed (187). 
There is still limited knowledge about the function of ATM in cancer and thus further studies 
are necessary. Besides genes whose involvement in cancer has already been investigated, 
we identified a large number of genes whose role in cancer has been unknown so far. 
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Further expression analysis as well as functional analysis for the cohort of genes analyzed 
would be of high interest.  
Approximately 90% of the genes up-regulated after Aza-dC treatment were also found to 
be up-regulated in cells after TSA treatment. These findings not only confirm the already 
known fact of synergy between Aza-dC and TSA but also emphasize the knowledge about 
the strong linkage between DNA methylation and histone protein modification.  
667 genes were synergistically up-regulated in at least one NSCLC cell line analyzed. 73% 
of these genes are involved in cancer related pathways including genes like MAL and PCAF. 
PCAF encodes a histone acetyltransferase which interacts physically and regulates the tumor 
suppressor PTEN. One important function of PTEN is to arrest cell cycle within the G1 phase 
and in this way inhibiting formation of malignancy (188). In addition, PCAF is known to be 
aberrantly methylated in esophageal squamous cell carcinoma. 
RECK which is a membrane-anchored glycoprotein important for regulation of different 
metalloproteinasesis in normal cells was among the genes identified to be up-regulated after 
induction with epigenetic active drugs. It is known to be down-regulated in several cancer 
types and to be a target for methylation in NSCLC. Chang et al. (189) identified a strong 
correlation between inactivation of RECK and formation of lymph node metastasis. In most 
of the cases down regulation is achieved by aberrant DNA methylation in the promoter 
region. RECK is even considered as gene of interest for prognosis of peritoneal metastasis of 
gastric cancer (190). Further studies are necessary. 
 The second whole genome approach for analyzing DNA methylation patterns of the 
cell lines A549, NCI-H1993, NCI-H2073 and NHBEC is the MeDIP-chip method. Major 
advantages of this method are applicability to tissue samples. Additionally, the MeDIP-chip 
technique identifies methylation directly in contrast to approaches using epigenetically 
active drugs which re-express methylated genes. Since the identification of genes in the 
MeDIP-chip methods is based on immunoprecipitation step of methylated DNA fragments.  
To test for efficient enrichment of methylated DNA fragments two quality control steps 
were performed. The first one was a qRT-PCR step using primers for genes known to be 
methylated and primers for genes known to be unmethylated. Housekeeping genes are 
known to be unmethylated in many types of somatic cells. GAPDH is a very famous 
representative of housekeeping genes. Thus, we chose this gene as reference gene in qRT-
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PCR analyses to identify and quantify unmethylated fragments in the samples. H19 was used 
as reference gene for methylated DNA fragments since, H19 is completely silenced by DNA 
methylation after completion of different developmental processes (191, 192). The 
combination of these genes in a qRT-PCR allows an optimal comparison of the presence of 
methylated and unmethylated DNA fragments.  As a second quality control step these two 
genes were included into the microarray as positive and negative control.  
Analyzing NSCLC cell lines with the MeDIP-chip method revealed a huge amount of genes 
important in cancer related pathways. We identified tumor-specific methylation of single 
genes as well as tumor-specific methylation of whole gene clusters. In particular, members 
of the PCDHA and the HOXA cluster were found to be frequently methylated. All 13 
representatives of PCDHA, namely PCDHA1, PCDHA2, PCDHA3, PCDHA4, PCDHA5, PCDHA6, 
PCDHA7, PCDHA8, PCDHA9, PCDHA10, PCDHA11, PCDHA12, and PCDHA13 were methylated 
in the NSCLC cell lines but were unmethylated in the NHBEC cell line analyzed. PCDH genes 
can be subdivided into clustered and non-clustered protocadherins. All genes encoded in the 
PCDHA gene cluster on chromosome 5 take part in the formation process of protocadherin. 
Overall, knowledge about the involvement of clustered protocadherins in cancer is limited 
(193). Recently, PCDHA was identified as target for aberrant methylation in breast cancer 
(194, 195). Moreover, methylation of protocadherin clusters was investigated in Wilms 
tumors using the MeDIP-chip approach revealing that most members of the PCDHA, PCDHB 
and PCDHC clusters are tumor-specifically methylated (196). However, in our study we 
observed that only members of the PCDHA clusters are tumor-specifically methylated but 
not members of the PCDHB and PCDHG. Its relevance in NSCLC is unknown so far. 
 Members of the homeo box protein family were identified as a second group of 
clustered genes which are frequently methylated in the NSCLC cell lines analyzed. In general, 
HOX genes are members of a transcription factor family and are involved in embryonic 
development and in the control of differentiation of adult hematopoietic cells (197). 85% of 
genes encoded in the HOXA gene cluster were tumor-specifically methylated in the cell lines, 
analyzed suggesting that methylation of members of these gene cluster seems to be crucial 
for the pathogenesis of NSCLC. This observation is in concordance with previously reported 
data. Rauch et al. (198) reported that all 4 HOX gene clusters on chromosome 2, 7, 12 and 17 
are preferential targets for methylation in lung cancer cell lines. Shiraishi et al. (199) 
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analyzed methylation of HOXA and HOXD cluster members in primary tumor samples and 
matching non-malignant lung tissue samples of 8 lung adenocarcinoma patients and found 
several of them to be tumor-specifically methylated. Identifying HOX genes to be tumor-
specifically methylated in our study suggests that HOX genes may play an important role in 
the pathogenesis of NSCLC (Heller et al. unpublished). 
These findings propose that not only expression of single genes is affected by DNA 
methylation but also whole gene clusters are regulated by DNA methylation in lung cancer. 
Further analyses are necessary to clarify if methylation of single genes attracts methylation 
to genes in the same cluster or if these genes were methylated independently from each 
other.   
Additionally, genes that are involved in either de-regulation of cell proliferation or cell 
death were found to be tumor-specifically methylated in the cell lines analyzed. 27 of the 
tumor-specifically methylated genes were affiliated to pathways important for these two 
physiological processes. Differential expression of PHOX2B was identified in a large number 
of studies about neuroblastomas (200, 201). To our knowledge, this is the first report 
showing that PHOX2B is silenced by DNA methylation and is related to the pathogenesis of 
NSCLC.  
21 genes commonly identified to be methylated by both methods used. These genes 
represent 45% of the genes identified as methylated by the MeDIP-Chip method. For 
example HOXA9 is known to be a transcription factor involved in embryogenesis and 
differentiation of adult cells (198). IRX2 encodes an iroquois-class homeo domain protein 
and is another transcription factor (202, 203). 
4560 genes were identified as up-regulated in at least one cell line after drug treatment 
proposing epigenetic regulation as important factor for their regulation. MeDIP-chip analysis 
identified 47 genes to be methylated in a statistically relevant manner. Only 0.5% of genes 
identified by Aza-dC/TSA treatment were additionally identified by the MeDIP-chip method. 
This situation can be related to the fact that treatment with Aza-dC and/or TSA does not only 
alter DNA methylation patterns of cells but is also a stress factor for treated cells. This leads 
to the conclusion that identifying DNA methylation by indirect methods gives an excellent 
first insight into DNA methylation patterns but results have to be verified by direct DNA 
methylation analysis to identify false positive results.  
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Overall, our results stress the importance of DNA methylation for the pathogenesis of 
NSCLC. This project is one step on the long path of understanding the molecular mechanism 
of NSCLC, however many further studies are necessary. 
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10 ABSTRACT 
Lung cancer is the number one of death reasons among cancer patients causing ~ one 
million deaths each year worldwide. Adenocarcinomas represent the predominant 
histological subtype of non-small cell lung cancers (NSCLC). Beside genetic aberrations, 
epigenetic changes lead to de-regulation of gene expression during the pathogenesis of lung 
cancer. The so far best studied epigenetic change in NSCLCs is DNA methylation. Several 
genes, including RASSF1A or DAPK have already been identified to be methylated in NSCLC. 
To gain further insight into DNA methylation changes in NSCLCs we performed two different 
approaches for whole genome DNA methylation analysis in three lung adenocarcinoma cell 
lines. The first approach is based on the observation that epigenetic changes are reversible. 
Thus, cell lines were treated with the epigenetically active drugs 5-aza-2’-deoxycytidine (Aza-
dC), a DNA methyltransferase inhibitor, and trichostatin A (TSA), a histone deacetylase 
inhibitor. Since synergistic effects of these two drugs are known cells were also treated with 
a combination of Aza-dC and TSA. Consequently, gene expression patterns of treated and 
untreated cells were compared by Affymetrix microarray analyses. Using this approach, we 
identified 4560 uniquely up-regulated genes after Aza-dC/TSA treatment. Since, Aza-dC and 
TSA are cytotoxic drugs up-regulation of certain genes may be due to secondary effects. To 
address this issue, we established an approach for direct identification of methylated DNA 
fragments: methylated DNA immunoprecipitation (MeDIP) combined with microarray 
analysis (MeDIP-chip). With this method methylation of ~28.000 CpG islands was analyzed in 
each of the 3 lung adenocarcinoma cell lines and in normal human bronchial epithelial cells 
(NHBEC). By comparing microarray data obtained from the adenocarcinoma cell lines and 
NHBE cells we identified 47 tumor-specifically methylated genes. Genes which were so far 
unknown to be de-regulated in lung cancer and which are affiliated to cancer associated 
pathways like cell differentiation, apoptosis or cell migration were identified (e.g. POU4F2, 
PAX6 and HOXA9). 21 out of the 47 genes identified were also found to be up-regulated 
after treatment with epigenetically active drugs.  
Results of the two whole genome level approaches were verified using methylation-
specific PCR (MSP). MSP analyses in NSCLCs and corresponding non-malignant lung tissue 
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samples obtained from 10 NSCLC patients verified the tumor-specific methylation of the 
genes identified.  
In conclusion, using genome-wide approaches for DNA methylation analysis we 
identified a large number of so far unknown methylated genes in NSCLC. 
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11 ZUSAMMENFASSUNG 
Um ein besseres Verständnis der Pathogenese des nicht-kleinzelligem Lungenkarzinoms 
zu erlangen, haben wir die Bedeutung der DNA Methylierung in NSCLC Zelllinien untersucht. 
Drei NSCLC Zelllinien wurden mit 5-aza-2'-deoxycytidine (Aza-dC) und/oder Trichostatin A 
(TSA) behandelt und das Geneexpressionsmuster von behandelten mit unbehandelten Zellen 
verglichen. Mit dieser Methode kann DNA Methylierung indirekt über die Analyse der 
differentiellen Gene Expression identifiziert werden. Wir haben 4560 Gene wurden 
identifiziert, deren Expression nach Behandlung mit den epigenetisch aktiven Agenzien in 
mindestens einer Zelllinie verstärkt war. 30% der verstärkt exprimierten Gene nach 
Behandlung mit Aza-dC wurden synergistisch hinauf reguliert nach Behandlung mit Aza-dC 
und TSA. Weiters wurden die drei NSCLC Zelllinien sowie „normal human bronchial 
epithelien cells“ (NHBEC) mit einer weiteren Genom-weiten DNA Methylierungsanalyse 
untersucht. Die Methode MeDIP-Chip wurde in den letzten Jahren entwickelt und kann DNA 
Methylierung direkt identifizieren. Basierend auf Immunopräzipitation werden in dieser 
Technik methylierte DNA Fragmente angereichert und mittels Microarray mit der 
Ausgangsprobe verglichen. Wir identifizierten 47 tumorspezifisch methylierte Gene. 45% 
dieser Gene waren auch in den Ergebnissen der ersten Methode präsent. Identifizierte Gene 
wurden durch eine genespezifische Methode, nämlich Methylierungs-spezifische PCR (MSP), 
bestätigt. Unter den identifizierten Genen befinden sich bereits bekannte Targetgene für 
Methylierung in NSCLCs sowie Gene, deren Methylierung bis dato unbekannt war. Eine 
Vielzahl der identifizierten Gene hat Einfluss auf Krebsassoziierte Signaltransduktionswege. 
Ein weiteres Resultat dieser Arbeit ist, dass neben der Methylierung einzelner Genen auch 
DNA Methylierung ganzer Gencluster wie HOXA und PCDHA identifiziert wurden.  
Insgesamt ist es uns gelungen, eine Vielzahl bis dato unbekannter Targetgene für DNA 
Methylierung zu identifizieren und somit, die Wichtigkeit der DNA Methylierung in der 
Pathogenese von NSCLC hervor zu heben.  
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